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ABSTRACT 
 
Colorectal cancer (CRC) is one of the most common human neoplasias. Epidemiological and 
preclinical studies have shown that 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3), the most 
active metabolite of vitamin D3, has wide but not fully understood antitumor activity. Most, if 
not all, 1α,25(OH)2D3 actions are mediated by vitamin D receptor (VDR), a member of the 
nuclear receptor superfamily of transcription factors whose expression is lost during CRC 
progression. Cystatin D (CST5 gene product) is an inhibitor of several cysteine proteases of 
the cathepsin family. Cystatin D has a more restricted pattern of tissue expression and 
narrower inhibitory profile than other members of the cystatin family, as well as an unknown 
biology. A previous transcriptomic analysis of 1α,25(OH)2D3 action on human colon cancer 
cells revealed CST5 as a candidate target gene.  
The results described in this Thesis show that 1α,25(OH)2D3 increases CST5 RNA and 
protein levels in human CRC cells. Consistently, diminished cathepsin L activity was 
detected in 1α,25(OH)2D3-treated cells. 1α,25(OH)2D3 promotes VDR binding to, and 
transcriptional activation of, the CST5 promoter. In cells lacking endogenous cystatin D, 
ectopic cystatin D expression inhibited cell proliferation, migration and anchorage-
independent growth. Moreover, cystatin D antagonized the Wnt/β-catenin signaling pathway 
and repressed c-MYC expression. Additionally, cystatin D repressed the epithelial-
mesenchymal transition inducers SNAI1, SNAI2, ZEB1 and ZEB2, and, conversely, induced 
E-cadherin and other adhesion proteins. Transcriptomic analyses have identified a panel of 
candidate target genes whose RNA levels in CRC cells are modulated by cystatin D. 
Furthermore, ectopic cystatin D expression blunted xenograft tumor growth in 
immunodeficient mice. CST5 knockdown using shRNA abrogated the antiproliferative effect 
of 1α,25(OH)2D3, attenuated E-cadherin expression, and increased c-MYC expression. 
Interestingly, mutant cystatin D proteins with reduced antiproteolytic activity preserve the 
antiproliferative but not the cell migration-inhibitory effects. In human CRC tumors, we found 
a strong correlation between the expression of VDR and E-cadherin and that of cystatin D. 
Additionally, the loss of cystatin D correlated with poor tumor differentiation. Our results show 
that CST5 acts as a tumor suppressor gene with unpredicted effects that may contribute to 
the antitumor action of 1α,25(OH)2D3 in colon cancer. 
 
 
 
 
  
RESUMEN 
 
El cáncer colorrectal (CRC) es una de las neoplasias de mayor incidencia y mortalidad. 
Estudios epidemiológicos y preclínicos indican que la 1α,25-dihidroxivitamina D3 
(1α,25(OH)2D3), el metabolito más activo de la vitamina D3, tiene una amplia pero no del 
todo conocida actividad antitumoral frente al CRC. La mayoría, si no todas, las acciones de 
la 1α,25(OH)2D3 están mediadas por el receptor de vitamina D (VDR), un factor de 
transcripción de la superfamilia de los receptores nucleares cuya expresión se pierde 
durante la progresión del CRC. La cistatina D (producto del gen CST5) es un inhibidor de 
varias cisteín–proteasas de la familia de las catepsinas. La cistatina D tiene un perfil más 
restringido de expresión tisular y un perfil de inhibición más limitado que otros miembros de 
la familia de las cistatinas, así como una biología poco conocida. Estudios transcriptómicos 
previos sugieren que CST5 es un gen diana de la 1α,25(OH)2D3 en células humanas de 
cáncer colon. 
Los resultados de esta Tesis indican que la 1α,25(OH)2D3 aumenta los niveles de RNA y 
proteína de CST5 en células de CRC humano. Consecuentemente, en las células tratadas 
con 1α,25(OH)2D3 se detectó una disminución en la actividad de la catepsina L. La 
1α,25(OH)2D3 promueve la unión de VDR al promotor del gen CST5 y su activación 
transcripcional. En células que carecen de expresión endógena de cistatina D, su expresión 
ectópica inhibió la proliferación, migración y crecimiento independiente de anclaje a sustrato. 
Más aún, la cistatina D antagonizó la ruta de señalización Wnt/β-catenina y reprimió la 
expresión de c-MYC. Además, la cistatina D reprimió la expresión de los genes inductores 
de transición epitelio-mesénquima SNAI1, SNAI2, ZEB1 y ZEB2, y, de manera opuesta, 
indujo la expresión de E-cadherina y otras proteínas de adhesión. Estudios transcriptómicos 
han identificado una serie de genes candidatos a ser regulados por cistatina D en células de 
CRC humano. In vivo, la expresión ectópica de cistatina D bloqueó el crecimiento de 
tumores xenotransplantados en ratones inmunosuprimidos. El silenciamiento del gen CST5 
utilizando shRNA inhibió los efectos antiproliferativos de la 1α,25(OH)2D3, atenuó la 
expresión de E-cadherina y aumentó la expresión de c-MYC. Versiones mutantes de 
cistatina D con reducida actividad antiproteolítica mantuvieron el efecto antiproliferativo pero 
no el inhibidor de migración celular. En tumores colorrectales humanos encontramos una 
fuerte correlación entre la expresión de VDR y E-cadherina y la de cistatina D. Además 
durante la progresión tumoral la pérdida de cistatina D se asocia con menor grado de 
diferenciación. Nuestros datos muestran que CST5 actúa como un gen supresor tumoral que 
puede contribuir a la acción protectora de la 1α,25(OH)2D3 frente al cáncer de colon. 
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ABBREVIATIONS 
 
3 
1α ,25(OH)2D3: 1α,25-dihydroxyvitamin D3 
25(OH)D3: 25-hydroxyvitamin D3 
9cRA: 9-cis retinoic acid 
ACF: aberrant crypt foci 
AF: activation function 
APC: adenomatous polyposis coli 
bHLH: basic helix-loop-helix 
CDK: cyclin-dependent kinase 
ChIP: Chromatin immnunoprecipitation 
CIN: chromosomal instability 
CK1: casein kinase 1 
CRC: colorectal cancer 
CT: threshold cycle 
CYP24: 24-hydroxylase 
CYP27A1: vitamin D3-25-hydroxylase 
CYP27B1: 25(OH)D3-1α-hydroxylase 
DBD: DNA-binding domain 
DBP: vitamin D-binding protein 
DHA: docosahexaenoic acid 
EMT: epithelial-mesenchymal transition 
FAP: familial adenomatous polyposis 
GAPDH: gliceraldehyde 3-phosphate deshydrogenase 
GI: gastrointestinal 
GSK: glycogen synthase kinase  
HAT: histone acetyltransferase 
HDAC: histone deacetylase 
HNPCC: hereditary nonpolyposis colorectal cancer 
HNSCC: head and neck squamous cell carcinoma 
ISC: intestinal stem cell 
LBD: ligand-binding domain 
LEF: lymphoid enhancer-binding protein 
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LRP: lipoprotein receptor-related protein 
Luc: Firefly luciferase 
MET: mesenchymal-epithelial transition 
MIN: microsatellite instability 
MMR: mismatch repair 
NICD: notch intracellular domain 
PAI: plasminogen activator inhibitor 
PBS: phosphate-buffered saline 
PI: propidium iodide 
PPAR: peroxisoma proliferator activated receptor 
PTH: parathyroid hormone 
RA: retinoic acid 
RAR: retinoid acid receptor 
RARE: retinoic acid response element 
Rluc: Renilla reniformes luciferase 
RUNX: runt-related transcription factor 
RXR: retinoid X receptor 
SDHA: succinate deshydrogenase complex, subunit A 
SFRP: secreted Frizzled-related protein 
shRNA: short hairpin RNA 
TBP: TATA-binding protein 
TCF: T-cell factor 
TGF: transforming growth factor 
TIMP: tissue inhibitor of metalloproteinases 
TR: thyroid hormone receptor 
tRA: all-trans retinoic acid 
UBC: ubiquitin C 
UVB: ultraviolet light 
VDR: vitamin D receptor 
VDRE: vitamin D response element 
ZO: zonula occludens 
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1. Vitamin D  
1.1 Biochemistry 
Vitamin D is a group of fat-soluble secosteroid prohormones (steroids in which one of the 
bonds in the steroid rings is broken), the two major forms are vitamin D3 (or cholecalciferol), 
synthesized by vertebrates, and vitamin D2 (or ergocalciferol), produced by invertebrates, 
fungi and plants.  
Vitamin D3 is naturally present in very few components of the human diet, and is also 
available as a dietary supplement, but this only contributes to 10% of total vitamin D3 in the 
body. The 90% remaining is produced in the skin when 7-dehydrocholesterol reacts with 
ultraviolet (UVB) light (wavelengths between 270–300 nm), with peak synthesis occurring at 
295-297 nm 212. These wavelengths occur daily within the tropics, daily during the spring and 
summer seasons in temperate regions, and almost never within the arctic circles. After 
photolytic conversion of 7-dehydrocholesterol in previtamin D3, this is spontaneously 
isomerized to vitamin D3 that enters the circulation and is transported bound to the carrier 
plasma protein vitamin D-binding protein (DBP) 119 (Figure 1). Vitamin D3 obtained from sun 
exposure, food, and supplements is biologically inert (prohormone) and must undergo two 
hydroxylations in the body for activation. First, vitamin D3 is hydroxylated in the liver to 25-
hydroxycholecalciferol (25(OH)D3 or calcidiol, the major circulating form of vitamin D) by the 
enzyme vitamin D3-25-hydroxylase (CYP27A1 and CYP2A) produced by hepatocytes, and 
stored until it is needed. Later, in the kidney, the 25(OH)D3-1α-hydroxylase enzyme 
(CYP27B1) catalyzes a second hydroxylation of 25(OH)D3, resulting in the formation of 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3 or calcitriol, the most potent form of vitamin D). 
Most of the physiological effects of vitamin D3 in the body are related to the activity of 
1α,25(OH)2D3 121. Although the kidney is the main responsible of the circulating 
1α,25(OH)2D3 synthesis, CYP27B1 is also expressed in other tissues as skin, bone, prostate, 
breast, lung and colon, where 1α,25(OH)2D3 acts in an autocrine and/or paracrine manner 
332.  
The catabolism of 1α,25(OH)2D3 and its metabolites is mediated by the oxidation of its 
lateral chain, initiated by the hydroxylation of 24’ position by ubiquitous 24-hydroxylase 
(CYP24). Subsequent oxidations generate metabolites less active till calcitroic acid, which is 
biologically inert and is excreted. The 1α,25(OH)2D3 plasma levels are tightly controlled by 
the regulation of CYP27B1 and CYP24 expression by parathyroid hormone (PTH) and 
1α,25(OH)2D3 itself 109,199. 
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Figure 1. Metabolism of 1α,25(OH)2D3. Key enzymes and tissues involved in 1α,25(OH)2D3 synthesis and 
catabolism are shown. 
 
1.2 Biological actions of 1α,25(OH)2D3 
1α,25(OH)2D3 is a pleiotropic hormone with endocrine, paracrine and, probably, autocrine 
actions 256. 1α,25(OH)2D3 is essential for promoting calcium absorption in the gut and 
maintaining adequate serum calcium and phosphate concentrations to enable normal 
mineralization of bone. It is also needed for bone growth and bone remodeling by osteoblasts 
and osteoclasts 120. These are known as classical actions of vitamin D 44. However, since 
1981 novel actions including antiproliferative, pro-apoptotic and prodifferentiation effects in 
normal and tumor cells have been described 38,56,221.  In addition, numerous studies have 
reported the inhibition by 1α,25(OH)2D3 of  tumor invasiveness and angiogenesis 45,110,221 and 
its importance as antimicrobial and immunomodulatory agent 10,177.  
These novel 1α,25(OH)2D3 actions suggest its use for the treatment of hyperproliferative 
disorders such as psoriasis and cancer. However, the toxicity due to the hypercalcemic effect 
of 1α,25(OH)2D3 at therapeutic doses restricts the latter treatment. Many analogs 
(deltanoids) with less hypercalcemic effect are at different preclinical and clinical 
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development stages as single or combinatorial treatment against several neoplasias 
(www.clinicaltrials.gov) 56,62. 
 
1.3 Mechanism of action of 1α,25(OH)2D3 
1.3.1 Vitamin D receptor (VDR) and genomic actions of 1α,25(OH)2D3  
1α,25(OH)2D3 exerts most of its biological effects through the interaction with a member of 
the superfamily of nuclear receptors, the vitamin D receptor (VDR).  Most normal and tumor 
cells express VDR and respond to 1α,25(OH)2D3 treatment. VDR has a domain structure 286 
homologous to that of the other nuclear receptors. Its 427 amino acids encompass a short N-
terminal activation-function 1 (AF-1) domain (A/B) that contributes to constitutive ligand-
independent receptor activation, a DNA-binding domain (DBD or “C”) containing two zinc-
fingers and also playing a role in receptor dimerization, a flexible "hinge" region (D) that 
includes nuclear localization signals and which is thought to confer rotational flexibility 
between the DBD and LBD and allow for receptor dimerization and interaction with the DNA, 
and finally the ligand-binding domain (LBD or "E"), whose C-terminal end also has ligand-
dependent transcriptional activation function (AF-2). 
VDR forms heterodimers with members of the same family, mainly the retinoid X receptor 
(RXR) and possibly also the thyroid hormone receptor (TR) 41,183,324. VDR and RXR are in 
constant movement between cytoplasm and nucleus. In absence of 1α,25(OH)2D3, VDR and 
RXR are able to heterodimerize in the cytoplasm and RXR modulates the importin α-
mediated VDR translocation  to the nucleus 324. In the nucleus, the VDR/RXR heterodimer 
interacts with specific DNA sequences known as vitamin D response elements (VDREs) 
present in its target genes. Usually, VDREs are direct repetitions of (A/G)G(G/T)TCA 
hexanucleotide spaced by three or four nucleotides (nt) (DR3 or DR4, respectively) or 
everted repetitions spaced by six to nine nt (ER6-ER9), and each receptor interacts with a 
hemisite 113,266,294. One or more VDRE have been identified in the promoter of 1α,25(OH)2D3 
target genes such as CYP24, p21CIP1, osteopontin, osteocalcin, insulin-like growth factor-
binding proteins (IGFBP)-1, -3, -5, cyclin C and transient receptor potential cation channel 
(TRPV) -5,-6 41. 
In the absence of 1α,25(OH)2D3, the VDR/RXR heterodimer is bound to DNA at VDRE and 
recruits co-repressor proteins as NCoR, SMRT and Alien/TRIP15. The co-repressors have 
intrinsic histone deacetylase activity (HDAC) or associate themselves with HDAC enzymes 
promoting chromatin compaction and target genes are silenced. Binding of 1α,25(OH)2D3 to 
VDR leads to a conformational change of the LBD switching co-repressors for co-activators 
belonging to p160/SRC family as SRC-1/NCoA-1, SRC-2/NCoA-2/GRIP1/TIF2 and SRC-
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3/RAC3. The interaction of co-activators with the AF-2 region of LBD recruits histone 
acetyltransferases (HAT) and chromatin-remodeling complexes as CBP/p300 and WINAC, 
respectively, that together mediate chromatin decompaction 273,286. It has been suggested 
that co-activators have a temporary interaction and subsequently, they are substituted by the 
VDR-interacting proteins complex (DRIP/TRAP). This complex recruits the RNA polymerase 
II and links VDR to the basal transcriptional machinery promoting gene activation. However, 
the precise order of interaction and action of the different complex is not yet established 286.  
Recent studies using microarrays show that about one third of 1α,25(OH)2D3 target genes 
are repressed 41,227, but how VDR activated by 1α,25(OH)2D3 can repress gene expression is 
a less characterized mechanism 148,262.  
 
1.3.2 Non-genomic effects of 1α,25(OH)2D3 
 
1α,25(OH)2D3, like other steroid hormones, can also induce rapid responses (seconds-
minutes to hours) independently of gene expression 213. These non-genomic effects can be 
mediated by a subpopulation of VDR localized in the cytoplasm or in the plasma membrane, 
or by another different receptor. Recent studies have localized VDR in the caveolae 
membrane fraction of different cell lines and associated with actin filaments near the plasma 
membrane 90,124. A few studies support that VDR mediates these rapid responses. Several 
non-genomic actions of 1α,25(OH)2D3 are blocked in VDR-/- mice osteoblasts and also by a 
mutant VDR lacking the first zinc finger necessary for DNA binding 69,330. 
Many non-genomic effects are triggered by 1α,25(OH)2D3 interaction with extranuclear 
receptors, VDR or others. Thus, opening of voltage-gated Ca2+ and Cl− channels, important 
for the rapid intestinal calcium absorption or the cytosolic calcium elevation (from the outer 
medium and/or intracellular sources), the activation or inhibition of different kinases (c-SRC, 
PKC (α, β, γ), PI3K, JNK, ERK and the activation of phospholipases (PL) C and D and/or 
phosphatases (PP1 and PP2A) are 1α,25(OH)2D3 non-genomic effects 28,36,147,213,214.    
 
1.3.3 Integration of genomic and non-genomic effects of 1α,25(OH)2D3   
Recent results of our laboratory have shown that 1α,25(OH)2D3 activates a non-genomic 
pathway beginning with the entry of Ca2+ from the external medium and continuing with the 
activation of RhoA GTPase and p38MAPK-MSK kinases. This pathway is necessary for the 
optimal regulation of 1α,25(OH)2D3 target genes, as well as for the interference with the 
transcriptional activity of β-catenin/TCF complexes. VDR is required for the activation of this 
signaling pathway, showing its dual function as nuclear transcription factor and as an 
extranuclear activator of non-genomic effects 220. 
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2. Colorectal cancer  
Colorectal cancer (CRC) is together with lung, breast and prostate one of the most frequent 
cancers worldwide 76,138. CRC is the result of the malignant transformation of epithelial cells 
lining the inner colon and rectum. CRC has an important geographic component; the 
incidence is greatest in industrialized countries where consumption of meats, fats and refined 
carbohydrates per capita is high 230. Other important risk factors beside diet and lifestyle are 
ethnicity and age. These data suggest an important role of environmental factors in the 
susceptibility to CRC cancer 111,189,218. Only a low percentage of CRC (between 5-10%) is 
attributable to hereditary factors. Thus is the case of two autosomal dominant syndromes 
characterized for the CRC development at an early age: familial adenomatous polyposis 
(FAP), caused by the heredity of a mutated copy of adenomatous polyposis coli (APC) tumor 
suppressor gene 101,149 and hereditary nonpolyposis colorectal cancer (HNPCC), caused by 
the mutation or epigenetic silencing of some mismatch repair (MMR) genes such as MSH2, 
MLH1, MSH6, PMS1 or PMS2 186,194,240.    
Most of CRC are sporadic and with a slow development, providing a great opportunity to 
an early detection. As many as 70% of CRC patients do not show evidence of metastasis. 
Surgical resection is the therapy of choice for localized tumors (50% of recurrence), but there 
is no satisfactory treatment when surgery is not curative or for advanced colon cancer 79,191.  
 
2.1 Biology of colonic epithelium 
The intestine is the segment of the gastrointestinal (GI) tract extending from the stomach to 
the anus and, in humans and other mammals, consists of two segments, the small intestine 
and the large intestine. The large intestine consists of the cecum and colon with the rectum 
in the final straight portion. The GI tract has a uniform general histology and can be divided 
into four concentric layers: The serosa or peritoneum is the outermost connective tissue 
layer that covers the abdominal cavity. The muscularis externa, bounded by serosa, 
consists of an inner circular layer and a longitudinal outer muscular layer; the coordinated 
contraction of these layers is called peristalsis. The submucosa consists of a dense irregular 
layer of connective tissue with large blood vessels, lymphatics and nerves branching into the 
mucosa and muscularis. Finally, the mucosa is the innermost layer of the GI tract that is 
surrounding the lumen. In the colon, this layer forms tubules of mucosal epithelium, 
perpendicular to the luminal surface, so-called Lieberkühn crypts, but lacks of intestinal villi 
(characteristic of the small intestine) (Figure 2). The mucosa is responsible for the 
processing and absorption of nutrients as well as for the compaction of the stool 263. 
Lieberkühn crypts are lined with short columnar epithelial cells, mostly mucus-secreting 
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Goblet cells, with interspersed water absorbing enterocytes and fewer peptide hormone-
secreting enteroendocrine cells.  
Figure 2. Schematic representation of colonic epithelium. In the colon, the mucosa layer forms the 
Lieberkühn crypts (tubules of mucosal epithelium, perpendicular to the luminal surface). In the crypt base are 
located the intestinal stem cells that differentiate into three different mature cell types (goblet cells, enterocytes, 
and enteroendocrine cells) while they migrate to the intercrypt table at the top of the crypt. The cells of the upper 
crypt do not have the capacity to regenerate. 
 
The GI epithelium is frequently worn away by the passing food. Therefore, every 4-5 days 
is renovated 263. Cells replacement and production in intestinal crypts is achieved by 
intestinal stem cells (ISCs) located at the Lieberkühn crypt base. These ISCs can produce 
progeny that undergo a limited number of divisions and ultimately can differentiate, as they 
migrate to the intercrypt table at the top of the colonic crypt, into the three different mature 
cell types described previously. When the cells mature, they gradually lose their stemness. 
Therefore, the cells of the upper crypt do not have the capacity to regenerate 32,187,247,263. 
Recently, Lgr5 and Prominin-1 (CD133) have been proposed as colon stem cells markers, 
allowing a more detailed study of crypts proliferation and differentiation processes 15,337.  
 
2.2 Cause and progression of intestinal neoplasia 
In humans, in contrast with mice, most of intestinal cancers affect the colon and not the small 
intestine. In 1990 Fearon and Vogelstein suggested that CRC is the result of the 
accumulation of alterations in certain oncogenes and tumor suppressor genes involved in 
proliferation and cell death control. Although the genetic alterations often occur in a certain 
order, the total accumulation of changes, rather than their order with respect to one another, 
is responsible for determining the tumor biological properties. According to the model few 
changes are sufficient for initiating tumorigenesis 74.  
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Figure 3. Model of CRC progression. The mutations related with a specific stage and their frequency 
(percentage of tumors) are shown. The mutator pathway, driven by epigenetic silencing or, less frequently, the 
mutation of MMR genes is not showed here. Modified from Fearon and Vogelstein 1990 74.  
 
Aberrant crypt foci (ACF) in colorectal mucosa are proposed to be the earliest 
morphological lesion in the development of neoplasia. There are two different types of ACF: 
dysplastic and non-dysplastic 215. Non-dysplastic ACF are more common, have K-RAS 
mutations and a limited potential to progress to adenoma and ultimately carcinomas. 
Dysplastic ACF show APC mutations and are the precursors of colon cancer 8,288. The 
mutation of a gene involved in the canonical Wnt/β-catenin pathway (APC or, less commonly, 
CTNNB1/β-catenin or AXIN) seems to be sufficient for adenoma initiation, while mutation of 
K-RAS or B-RAF and subsequent alterations in the transforming growth factor (TGF)-β 
pathway (SMAD4, SMAD2 or TGFβR2 genes) confer additional malignant features to the 
adenoma 98,253. The progression towards carcinoma involves the inactivation of TP53 gene in 
50% of colon tumors 126.  The mechanism involved in the acquisition of invasiveness 
properties and metastatic capacity is less known. Loss of E-cadherin and ephrin B receptors 
(EPHB) expression and modification the pattern of claudin 1 expression have been related 
with these processes 21,57 (Figure 3). 
This is known as the suppressor pathway and occurs in 85% of sporadic colon cancer and 
FAP patients. It is associated to chromosomal instability (CIN) with allelic loss and 
aneuploidy due to APC and TP53 mutations 80,126,253. In addition, the epigenetic silencing or 
less frequently, the mutation of MMR genes drives a second via for CRC, the mutator 
pathway. These tumors have a normal karyotype but show microsatellite instability (MIN). 
This pathway causes the HNPCC and 15% of sporadic CRC 129,239. 
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2.3 Importance of Wnt/β-catenin pathway in CRC 
The members of Wnt family are secreted cysteine-rich glycoproteins that participate in 
multiple developmental events during embryogenesis and have also been implicated in adult 
tissue homeostasis 179. In recent years numerous studies have shown that Wnt signaling is 
very often deregulated in pathological conditions. It is well established that the canonical or 
Wnt/β-catenin signaling pathway is aberrantly activated in a large number of hereditary and 
sporadic cases of CRC 100. In normal epithelial cells, in the absence of Wnt stimulation, 
cytoplasmic β-catenin levels are normally kept low through continuous proteasome-mediated 
degradation, which is controlled by a multiprotein complex containing the scaffold protein 
Axin, the tumor suppressor gene product APC, as well as the casein kinase 1 (CKI), and 
glycogen synthase kinase 3 (GSK3β), among others. In the nucleus prospective Wnt target 
genes are in a repressed state 47,197,241 (Figure 4, left panel).   
Wnt factors activate responding cells by interacting with the Frizzled (Fz) seven-span 
transmembrane receptors together with the low-density lipoprotein receptor-related proteins 
5 and 6 (LRP5/6). The binding of Wnt to the receptors leads to activation of the 
phosphoprotein Dishevelled (Dvl) that possibly recruits Axin or inhibits GSK3β, disrupting the 
degradation complex and blocking β-catenin degradation. As β-catenin levels rise, it 
accumulates in the nucleus, where it interacts with DNA-bound T-cell factor (TCF), and 
lymphoid enhancer-binding protein (LEF) family members to activate the transcription of 
target genes 47,100,179,197,241 (Figure 4, right panel).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Wnt/β-catenin pathway. In 
the absence of Wnt stimulation, β-
catenin is associated with a multiprotein 
complex containing APC, axin, CKI and 
GSK3β proteins. This complex 
phosphorylate and label β-catenin for 
proteasome-mediated degradation (left). 
Wnt factors inhibit the phosphorylation of 
β-catenin, that accumulates in the 
nucleus where interacts with TCF/LEF 
family members and activates the 
transcription of target genes (right). 
Modified from Cell signaling technology. 
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The Wnt/β-catenin signaling pathway has several antagonists that can be divided into two 
different classes. Both prevent ligand-receptor interactions, but by different mechanisms: 
members of the first class, which include the secreted Frizzled-related protein (SFRP) family, 
Wnt inhibitory factor-1 (WIF) and Cerberus, primarily bind to Wnt proteins; the second class 
comprises certain members of the Dickkopf (Dkk) family, which bind to the LRP subunit of 
the Wnt receptor complex 144. In addition, there are several intracellular pathways that 
interfere Wnt signaling 315. 
Homeostasis of the intestinal epithelium is maintained by the balance of cell proliferation, 
differentiation, and apoptosis. Although many signaling pathways such as BMP, Sonic 
Hedgehog and Notch are involved in maintaining this equilibrium, Wnt signaling is the main 
driver of self-renewal in the intestinal epithelium (reviewed in 47,81,252,263,305). 
Wnt signaling is active at the bottom of the crypts 242,303. In fact, ISCs show nuclear β-
catenin and express β-catenin/TCF4 target genes 100,303. The activity of β-catenin/TCF4 
complex is switched off as cells migrate upwards and enter the differentiated cell 
compartment 303. Despite many efforts, the location of the source of Wnt ligands has not 
been elucidated yet. Several Wnt family members are expressed in crypt epithelial cells, thus 
suggesting paracrine or autocrine signaling in the epithelium 304. In addition, mesenchymal 
cells surrounding the crypt bottom have also been proposed as a putative Wnt source 7,125,303.  
 
3. Effects of 1α ,25(OH)2D3 in colon cancer  
3.1 Vitamin D3 status and colorectal cancer 
Studies using animal models show that a Western-style diet (poor in vitamin D) increases the 
CRC and other neoplasias risk 204,258,321. In mutant APCmin mice, that develop polyps in 
normal conditions, diets with low vitamin D content increase the number of polyps and 
diminish the survival in contrast to diets rich in vitamin D 323. Moreover, in APCmin mice as 
well as other animals with chemical carginogen-induced colon tumors, 1α,25(OH)2D3 (or its 
analogs) treatment reduces the total tumor load 24,72,123,133,145,290. 
Ecological and epidemiological studies have demonstrated that solar radiation exposure 
and 25(OH)D3 serum levels are inversely correlated with colon cancer risk 78,86,99,289. Meta-
analysis and cancer prevention trials indicate that vitamin D3 supplementation to achieve a 
level of 82 nM of 25(OH)D3 can lower the incidence of CRC by 50% 56.  The results of two 
independent prospective studies with contradictory conclusions have been published 167,311. 
However, both studies have deficiencies (low vitamin D3 doses, limited number of colon 
cancer cases) that prevent a definitive conclusion. In 2008, the International Agency for 
Research on Cancer (IARC), from the World Health Organization (WHO), has issued the 
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Vitamin D and cancer report, where it is recognized that a causal link between vitamin D3 
and colorectal cancer is probable, but more prospective clinical trials and large-scale 
observational studies are needed. 
 
3.2 Effects of 1α,25(OH)2D3 in colon cancer cells 
The anticancer activity of 1α,25(OH)2D3 in colon cancer cells stems mainly from the inhibition 
of proliferation and the induction of apoptosis and differentiation. The growth-inhibitory action 
of 1α,25(OH)2D3 has been observed in many human colon cancer cell lines and also in 
cultured primary human colon adenoma- and carcinoma-derived cells 108,180,225,295,335. This 
antimitotic action is mediated by the induction of G0/G1 cell-cycle arrest as a result of the up-
regulation of the cyclin-dependent kinase (CDK) inhibitors p21WAF1/CIP1 and p27KIP1, as well as 
the repression of transcription factor Id2. Furthermore, 1α,25(OH)2D3 regulates many other 
genes related to proliferation including c-MYC, c-FOS and c-JUN and by interfering with 
certain signaling pathways that control epithelial cell growth (EGF, IGFII) 95,227. 
In addition to cell cycle inhibition, 1α,25(OH)2D3 induces apoptosis in colon cancer cells by 
the regulation of genes that control death pathways. Mainly, 1α,25(OH)2D3 upregulates the 
pro-apoptotic protein BAK 58,227. The apoptosis induced by 1α,25(OH)2D3 did not require an 
intact TP53 tumor suppressor gene. This would allow the use of 1α,25(OH)2D3 or its analogs 
for cancer treatment independently of the tumor TP53 status 58,109. 
The antiproliferative action of 1α,25(OH)2D3 and its analogs is commonly linked to 
stimulation of cell differentiation. 1α,25(OH)2D3 increases the number of intermediate 
filaments, desmosomes, and microvilli 108,110. Alkaline phosphatase activity, widely 
considered as a colon differentiation marker, is also induced by 1α,25(OH)2D3 in primary 
cultured colon carcinoma cells and in colon cancer cell lines 58,295. Our group has described 
the epithelial differentiation promoted by 1α,25(OH)2D3 in SW480-ADH cells, a subpopulation 
of SW480 colon adenocarcinoma cells that express VDR 225. This differentiation is 
associated with the induction of E-cadherin expression, the main component of adherens 
junctions. In addition, 1α,25(OH)2D3 induces the expression of the components of tight 
junctions occludin, Zonula occludens (ZO)-1, ZO-2 and vinculin 225. Moreover, 1α,25(OH)2D3 
inhibits the Wnt/β-catenin pathway (see section 2.3) and represses its target genes, 
contributing to the maintenance of a differentiated phenotype and the inhibition of cell cycle 
225. The effects of 1α,25(OH)2D3 over E-cadherin and β-catenin expression have also been 
observed in other colon cancer cell lines as HT-29, CaCo2, SW1417 and LS174T 225. 
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4. Cell adhesion in epithelial tissue  
4.1 Adherens junctions 
Together with tight junctions and desmosomes, adherens junctions are the molecular 
complexes responsible of cell-cell adhesion. Adherens junctions play a key role in initiating 
and stabilizing cell-cell contacts. In addition, they enhance the ability of the cell to sense and 
respond to its environment, for instance, by bringing neighbor cells together and therefore 
allowing activation of membrane receptors, which bind ligand tethered-ligands. Adherens 
junctions are dynamic structures with very precise and fast regulation. Their main 
components are: cadherins, β-catenin, p120-catenin and actin cytoskeleton structures 104 
(Figure 5). 
 
 
 
Figure 5. Adherens junctions. Schematic representation of E-cadherin interactions. Through its ectodomain E-
cadherin establishes homotypic interactions with E-cadherin molecules of neighboring cells in a calcium-
dependent manner. The intracellular domain of E-cadherin interacts with α-, β-, and p120-catenin that stabilize E-
cadherin in the membrane and connect it to the actin cytoskeleton. From van Roy and Berx 2008 307.  
4.1.1 E-cadherin  
E-cadherin (encoded by CDH1 gene) is primarily expressed in epithelial cells and is the core 
transmembrane protein of the adherens junctions. Its ectodomain establishes early cell-cell 
contacts through individual and relatively weak homotypic interactions with E-cadherin 
molecules of neighboring cells in a calcium-dependent manner. This initial event typically 
takes place at the tip of filopodial or lamellipodial projections termed puncta. The sequential 
binding of several catenins to E-cadherin cytoplasmic tail stabilizes E-cadherin in the 
membrane and connects it to the actin cytoskeleton and to other signaling molecules (Figure 
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5). These events allow contact strengthening by formation of cadherin clusters through the 
assembly of adjacent puncta that spread laterally generating zipper-like structures, which 
finally seal the membranes (reviewed in 112). In many epithelial-derived tumors, loss of E-
cadherin correlates with an increase in tumor cell invasiveness and motility, a process known 
as epithelial-mesenchymal transition, which points to a tumor suppressor role for E-cadherin 
(reviewed in 291).  
 
4.1.2 p120-catenin  
p120-catenin (p120ctn) is a key regulator of adherens junctions stability. p120ctn binding to 
E-cadherin in its juxtamembrane domain prevents cadherin internalization and degradation. 
Conversely, p120ctn dissociation from E-cadherin promotes cadherin recycling or 
degradation by inducing vesicle formation. Some molecules have been proposed as positive 
(afadin, Rap1) or negative (Hakai, presenilin-1) regulators of the p120ctn-E-cadherin 
interaction 320. 
Decrease or even complete silencing of p120ctn expression, accompanied by a 
downregulation of E-cadherin levels, is found in several human tumors (i.e. colon, prostate, 
breast and lung) 6. Paradoxically, established tumor cell lines rarely present p120ctn 
downregulation 53.  
 
4.2 Tight junctions 
The epithelial tight junction, or zonula occludens (ZO), seals cells together at a subapical 
location and functionally separates the plasma membrane into an apical and a basolateral 
domain and serves as a selectively permeable barrier to regulate paracellular diffusion. This 
junction is one of the most characteristic structural markers of the polarized epithelial cell. 
Some components of tight junction are structural proteins as ZO-1 and transmembrane 
proteins such as claudins and occludins 73,94,193. 
 
4.2.1 Occludin  
Occludin is a four-pass integral plasma-membrane protein located specifically at tight 
junctions. Numerous studies have indicated that occludin plays an important role in the 
regulation of tight junction integrity. However, recent studies indicated that tight junctions are 
formed in the absence of occludin and questioned the role of occludin in their assembly 254. 
The cytoplasmic domain of occludin may be involved in the regulation of tight junctions 
through intracellular signaling. Occludin directly interacts with c-Src, ERK1/2, PP2A, and PP1 
19,20,261. Therefore, occludin is likely to play a regulatory role in tight junction integrity. 
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5. Epithelial-mesenchymal transition  
An epithelial-mesenchymal transition (EMT) is a biological process that allows a polarized 
epithelial cell, which normally interacts with basement membrane via its basal surface, to 
undergo multiple biochemical changes that enable it to assume a mesenchymal cell 
phenotype. This includes enhanced migratory capacity, invasiveness, elevated resistance to 
apoptosis, and greatly increased production of extracellular matrix (ECM) components 141. 
The completion of an EMT is signaled by the degradation of underlying basement membrane 
and the formation of a mesenchymal cell that can migrate away from the epithelial layer in 
which it originated. The phenotypic plasticity afforded by an EMT is revealed by the 
occurrence of the reverse process, a mesenchymal-epithelial transition (MET), which 
involves the conversion of mesenchymal cells to epithelial derivatives. Relatively little is 
known about this process (reviewed in 142). 
 
 
 
 
Figure 6. Drivers and mediators of EMT. In 
early stage tumor cells (green) the accidental 
overexpression of master regulators of EMT, 
such as Twist, Snail, Slug, ZEB1 and ZEB2, 
leads to dramatic changes in gene expression 
profile and cellular behavior. These EMT-related 
proteins repress the expression of E-cadherin 
via E boxes in its promoter and trigger 
expression of an entire EMT transcriptional 
program. Modified from Kang and Massagué 
2004 143.  
 
 
A hallmark of EMT is the loss of E-cadherin expression. This loss increases tumor cell 
invasiveness in vitro and contributes to the transition of adenoma to carcinoma in animal 
models 291. Several developmentally important genes that induce EMT have been shown to 
act as E-cadherin repressors. Thus, Snail (SNAI1 and SNAI2), zinc-finger E-box binding 
homeobox (ZEB: ZEB1 and ZEB2) and basic helix-loop-helix (bHLH: E47, TWIST and E2-2) 
families mediate the transcriptional repression of E-cadherin (274 and references therein). The 
expression patterns of Snail, ZEB and bHLH factors in different human carcinomas, together 
with functional studies, indicate that the various factors have different roles during tumor 
progression, with a more prominent role for SNAI1 in the induction of EMT in primary tumors, 
whereas the other factors are involved in maintaining the migratory phenotype 233,234 (Figure 
6).  
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5.1 Snail family factors 
SNAI1 (Snail) and SNAI2 (Slug), members of the Snail superfamily, are zinc-finger 
transcription factors that share a common organization with a central region that is highly 
divergent between them. In Drosophila these proteins mediate the development of the 
mesoderm, neuroectoderm and the other organs 16. As a suppressor of E-cadherin 
expression, Snail binds to E-boxes (CANNTG) present in the CDH1 gene promoter, and 
represses its transcription 22,39. In addition, induction of Snail expression triggers a complete 
EMT 39,103. 
An inverse correlation between E-cadherin and Snail expression has been described in 
cultured lines established from oral squamous cell carcinoma, melanoma, pancreatic and 
hepatocellular carcinoma 122,139,244,325. Moreover, previous studies of our laboratory showed 
that SNAI1 expression was associated with the downregulation of VDR in CRC, with 
therapeutic implications for vitamin D treatment of Snail-negative tumors 169. More recently, 
our group also showed that SNAI2 is able to repress VDR alone or in cooperation with SNAI1 
168.  
 
5.2 ZEB family factors 
The ZEB family of transcription factors contains two members, ZEB1 and ZEB2. They are 
characterized by the presence of two zinc-finger clusters at each end and a central 
homeodomain. ZEB factors are expressed during development in the central nervous 
system, heart, skeletal muscle and haematopoietic cells 233. These transcription factors 
repress E-cadherin by binding to paired E-box sites in the proximal promoter. Both factors 
have been shown to induce EMT, and to participate in TGFβ signaling through binding to 
Smad co-activators, although the links between these two processes had not been clearly 
defined 209,245,246. 
 
5.3 bHLH family factors 
The bHLH proteins have a common structure with two parallel amphipatic α-helices joined by 
a loop, required for dimerization, and one helix containing basic amino-acid residues that 
facilitate DNA binding. The bHLH proteins can be classified into discrete categories. TWIST1 
is a member of class I (also known as E-proteins) bHLH proteins.  It has been implicated in 
cell lineage determination and differentiation. TWIST1 is overexpressed in various human 
solid tumors including numerous types of carcinomas as well as sarcomas, gliomas, 
neuroblastomas, and melanomas 64,68,118,164,216,322,334. Moreover, exogenous overexpression 
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of TWIST1 increases the invasive and metastatic abilities of human cancer cells by 
promoting the downregulation of E-cadherin and the induction of EMT 164,192,322. 
 
6. Cystein cathepsins  
Degradation of proteins is brought about by proteolytic enzymes, proteases, which based on 
their catalytic mechanisms can be sorted into five major classes; the serine-, cysteine-, 
aspartic-, threonine-, and metallo-proteases. 
Cathepsins are lysosomal peptidases, which belong mainly to the cysteine, but also to 
serine or aspartic protease classes. The human cysteine cathepsin family comprises 11 
members (cathepsins B, C, H, F, K, L, O, S, V, W X/Z). Some of them are ubiquitously 
expressed, such as cathepsins B, L, H and C, whereas several newly found family members 
as cathepsins K, W, and X are expressed in specific cells and tissues 35,159,317,319. The most 
important human cysteine cathepsins are cathepsins B, H, L, and S, which have common 
ancestors and are related to papain. 
Cathepsins participate in general protein turnover and can also perform specific functions 
in neovascularization 200, cell growth, antigen presentation, bone remodeling, and tissue 
homeostasis (reviewed in 296,300). Interestingly, cathepsins also have a role outside the 
lysosomes. When cathepsins are secreted into the extracellular space, they participate in 
degradation of the ECM or induction of fibroblast invasive growth, and when they are 
released into the cytosol they may execute a programmed cell death 75,153,296.  
 
 
 
 
 
Figure 7. Multiple roles for cysteine 
cathepsins during tumor progression. 
The RIP1-Tag2 model∗ of islet cell 
carcinogenesis is used to illustrate  that 
cysteine cathepsins are collectively 
important for tumor angiogenesis, cell 
proliferation, tumor growth, and tumor 
invasion. Specific cathepsin are shown in 
each case. From Joyce and Hanahan 
2004140. 
 
                                                        
∗ For explanation see page 85. 
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Cysteine cathepsins have been implicated in multiple physiological disorders and also in 
tumor progression, at early steps of tumor invasion and angiogenesis, and at late steps of 
metastasis and drug resistance 140 (Figure 7). 
 
7. Cystatins: protein inhibitors of cysteine cathepsins  
Cystatins are protein inhibitors of cysteine proteases of the papain family 17,297,298. They 
constitute a powerful regulatory system for endogenous cysteine proteinases, which are 
often secreted or leaking from the lysosomes of dying cells or diseased cells. Cystatins 
inactivate target proteases reversible and competitively by indirect blockage of the catalytic 
center of these enzymes, thereby preventing substrate docking and cleavage.  They form 
very stable bimolecular complexes with the proteases, keeping them inactive for hours or 
weeks. Cystatins are widely distributed in animals, plants and protozoa, both intracellularly 
and extracellularly, which indicates an important physiological role 17,132,298. 
Cystatins are all related by structure and function to an inhibitor of cysteine proteinases 
that was first described in egg white and called as chicken egg white (CEW) cystatin. 
Cystatins have been evolutionary related forming the Cystatin Superfamily∗. The members 
of the superfamily were grouped into three families or “types” on the basis of their location, 
size and complexity of polypeptide chains 18,255. Type 1 cystatins are found primarily 
intracellularly, contain about 100 amino-acid residues (∼ 11 KDa) and lack disulfide bonds. 
There are two human representatives, cystatin A and B. The type 1 cystatins have been 
called “stefins” to stress their difference from other cystatin superfamily members. Type 2 
cystatins are mainly extracellular secreted proteins, contain about 120 amino-acid residues 
(∼ 14 KDa) and two intrachain disulfide bonds. The salivary cystatins (cystatin D and 
others), cystatin C, E/M and CEW cystatin belong to this family. Type 3 cystatins comprise 
the plasma kininogens and may therefore also be called the kininogen family. They are multi-
domain proteins with high molecular weight (∼60-120 KDa). They contain additional disulfide 
bonds and are also glycosylated. There are three types of kininogens, the low molecular 
weight kininogens (LMWK), and high molecular weight (HMWK), and T-kininogens, only 
found in rats.  
                                                        
∗  In the recently developed MEROPS database (http://merops.sanger.ac.uk) proteases and their inhibitors are 
classified into clans and families according to their evolutionary relationship. Proteases and/or inhibitors with 
statically significant similarities in amino-acid sequence are grouped into families. Clans are formed by related 
families. The cystatins entered into the classification schemes to date all belong to MEROPS Family I25 of Clan 
IH. 
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7.1 Type 2 cystatins 
Type 2 cystatins are synthesized as preproteins with a signal peptide and, as mentioned 
previously, the members of this family are mainly extracellular, secreted proteins, although 
some have also been found intracellularly 1,2,105,202.  The family includes mammalian 
cystatins: cystatin C of several different species 70,102,117, cystatin D 82,83, cystatin E/M 
206,279,331, cystatin F/leukocystatin 105,198,207, cystatins S, SA and SN 134-136, and also CEW 
cystatin 299. 
The best studied representatives of type 2 cystatins are CEW cystatin and human cystatin 
C, the latter being the most abundant of the inhibitors of the cystatin superfamily in all human 
body fluids examined, with the highest concentration in seminal plasma and cerebrospinal 
fluid 1,2,217. Recently, cystatin C has been proposed as a useful indicator of glomerular 
filtration rate (reviewed in 170). In addition, cystatin C has been proposed as a TGFβ receptor 
antagonist, playing important roles in tumor progression275,276. 
Cystatin E/M has only ∼ 30% sequence identity with other type 2 cystatins and, unlike all 
other human type 2 cystatin genes, it is not located on chromosome 20, but on chromosome 
11 281. Cystatin E/M is quite ubiquitous and is expressed in a variety of normal human tissues 
206,279. Cystatin E/M has been widely studied because of its role as tumor suppressor mainly 
in breast cancer 150,270,333. 
 
7.2 Cystatin D 
Cystatin D was first identified as the product of a gene located in the cystatin multigene locus 
on chromosome 20 84 with a high degree of homology to the cystatin C gene. It contains all 
the classical features of a type 2 cystatin (Figure 8).  
Figure 8. Cystatin D structure and 
comparison with CEW cystatin. (A) 
Amino-acid sequence of the cystatin D 
form crystallized, recombinant human 
cystatin D. The secondary structure 
elements are indicated in yellow for α-
helix and blue for β-sheet. The motifs 
known to be important for the inhibition 
of papain-like enzymes by other 
cystatins are marked by red boxes, 
and some well-conserved residues in 
them are indicated according to human 
cystatin C numbering. The putative 
legumain-binding site (BSL) is also 
indicated, and the presence of an Asn 
residue in this loop is pointed out 
(underlined). The position of the 
residue corresponding to a gene 
polymorphism (Cys/Arg) is marked by 
an arrowhead. (B) Ribbon representation of the cryo structure of human cystatin D viewed from the front (left) and 
representations of the aligned structures of human cystatin D (in magenta) and CEW cystatin (in cyan) are viewed 
from the front (middle) and from the C-terminal end of the α-helix (right). Modified from Alvarez-Fernandez et al. 
2005 5. 
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Cystatin D is produced as a preprotein of 142 amino-acid residues, the first 20 residues 
constitute a typical signal peptide 5,82. Its complete amino-acid sequence displays 55% 
identical residues compared with the cystatin C sequence, with well conserved sequence 
motifs known to be essential for cysteine peptidase inhibition 82 (Figure 9).  
However, cystatin D has a narrower inhibitory profile than other cystatins: it inhibits 
cathepsin S, H and L, but not cathepsin B 12,82. Moreover, cystatin D also has a more 
restricted pattern of tissue expression and is only found in parotid and submandibular glands 
as well as in saliva, and in small amounts in tears, but could not be detected in seminal or 
blood plasma, milk or cerebrospinal fluid 83. Two alleles of the cystatin D gene are known, 
coding for either Cys or Arg as residue 26 11. It has been shown that this variation has no 
effect on the enzyme-binding properties of the inhibitor 12.                     
 
 
Figure 9. Alignment of several members of cystatin superfamily. Sequence alignment of cystatin D and 
known type 1 and 2 cystatins (human cystatin A, human cystatin B, CEW cystatin, human cystatin C from the 
dimer structure, and the plant cystatin, oryzacystatin). The conserved papain-binding site is marked by boxes in 
magenta. The red asterisk indicates the position of the Asn residue, which is necessary for legumain inhibition. 
Arrows indicate the two conserved disulfide bridges in type 2 cystatins. From Alvarez-Fernandez et al. 2005 5. 
 
 
Even though cystatin D was already described in 1991 82 little is know about its biology or 
function besides it may play a protective role against proteinases present in the oral cavity.  
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1α,25(OH)2D3 is one of the most important regulators of gene expression in higher 
organisms, and numerous evidences support a preventive and perhaps therapeutic effect of 
1α,25(OH)2D3 in colon cancer. 
Previous transcriptomic studies of our laboratory showed that 1α,25(OH)2D3 changes 
drastically the gene expression profile in human colon cancer cells. The level of CST5 RNA 
in SW480-ADH cells increased following 1α,25(OH)2D3 treatment. 
The aim of this Thesis has been to analyze the relation between 1α,25(OH)2D3 and cystatin 
D and their biological activity in human colon cancer. 
 
The main goals have been: 
 
1. To validate and analyze the mechanism of the 1α,25(OH)2D3-mediated regulation of 
cystatin D expression, as well as the role of this protease inhibitor in the effect of 
1α,25(OH)2D3 on human colon cancer cells. 
 
2. To characterize the putative antitumor actions of cystatin D in colon cancer. 
 
3. To study cystatin D expression in human colon tumors. 
 
4. To examine the gene expression profile induced by cystatin D in human colon cancer 
cells. 
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1. Cell Culture  
Several human colon cancer cell lines including SW480-ADH, SW480-R, HCT116, LS174T, 
Colo205, and CaCo2, as well as the embryonic human kidney cell line HEK-293T were used.  
The sublines SW480-ADH and SW480-R, provided by Drs. F. X. Real (CNIO, Madrid) and 
Antonio García de Herreros (Institut Municipal d´ Investigació Mèdica, Barcelona), were 
obtained from SW480 cells by limit dilution. These cells maintain, in a stable way, their 
different morphology and response to 1α,25(OH)2D3. Cells were maintained in RPMI medium 
supplemented with 10% FBS (Invitrogen), 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Treatment with 1α,25(OH)2D3 were performed in RPMI supplemented with 
charcoal-treated serum to remove liposoluble hormones. 1α,25(OH)2D3 was provided by Drs. 
R. Boullion and M. Verstuyf (Leuven University, Belgium). As control, in each experiment the 
equivalent volume of isopropanol (vehicle) was used. Unless another specific mention, cells 
were treated with 100 nM of 1α,25(OH)2D3 or vehicle for the times indicated in each case. In 
certain experiments, cells were treated with 9-cis retinoic acid, all-trans retinoic acid or 
docosahexaenoic acid (all from Sigma), and ethanol was then used as vehicle. Actinomycin 
D (2 µg/ml in ethanol, Sigma), an inhibitor of transcription by RNA polII, or cycloheximide (8 
µg/ml in DMSO, Sigma) an inhibitor of protein synthesis were used in certain experiments. 
Phase-contrast images of culture cells were captured with a Leica DC300 digital camera 
mounted on an inverted Leitz Labovert FS Microscope. All the images were processed using 
Adobe Photoshop CS2 software. 
 
2. Normal and tumor tissue samples from CRC patients  
Normal and tumor tissue samples from 32 patients with colon cancer were analyzed by 
western blot. All patients gave written informed consent and the protocol was approved by 
the Research Ethics Board of the Hospital Universitario Puerta de Hierro, Madrid. Samples 
were obtained immediately after surgery, immersed in RNA later (Ambion-Applera), snap-
frozen in liquid nitrogen and stored at -80ºC until processing. Tumors were considered 
sporadic since they do not show familiar or clinical history of FAP or HNPCC. These tumors 
were examined by two different pathologist for: (a) confirm adenocarcinoma diagnostic and 
presence of at least 75% of tumor tissue in the sample, (b) establish the histological level of 
the tumor, and (c) verify the absence of tumor cells in normal tissue. 
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3. Antibodies  
The different primary and secondary antibodies used in the experiments, as well as their 
origin and concentrations are shown in tables below. 
 
Table I. Primary antibodies 
Species Application 
Antigen Monoclonal Polyclonal WB IF References 
c-MYC Mouse  1/250  Santa Cruz Biotechnology 
Cyclophylin A  Rabbit 1/1000  Upstate 
Cystatin C  Goat 1/1000  R&D Systems 
Cystatin D  Rabbit 1/200 1/100  Prof. C. López-Otín 
Cystatin SN Mouse  1/250  R&D Systems 
E-cadherin Mouse  1/2000 1/100 BD Transduction Laboratories 
Lamin B Mouse  1/2000  Santa Cruz Biotechnology 
Occludin  Rabbit 1/2000 1/100 Zymed 
p120-catenin Mouse  1/1000 1/100 Prof. A. Reynolds 
Snail1  Rat 1/20  Dr. K-F. Becker 
VDR Rat  1/1000  Chemicon 
β-actin                        Goat 1/2000  Sigma 
β-catenin Mouse  1/1000 1/100 BD Transduction Lab. 
WB: Western blot, IF: immunofluorescence 
 
 
 
 
Table II. Secondary antibodies 
Name, antigen Dilution Company 
HRP-conjugated anti-rabbit IgG 1/10000 MP Biomedicals  
HRP-conjugated anti- mouse IgG 1/10000 Promega 
HRP-conjugated anti-goat IgG 1/5000 Santa Cruz Biotechnology 
HRP-conjugated anti-rat IgG 1/5000 Santa Cruz Biotechnology 
Alexa Fluor 488, goat anti-rabbit 1/250 Molecular Probes 
Alexa Fluor 488, donkey anti-mouse 1/100 Molecular Probes 
HRP: horseradish peroxidase 
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4. Oligonucleotides  
4.1 Oligonucleotides for CST5 promoter cloning 
Table III. 
Primers Sequence AT 
F: ACGCGTCCGCAGGATCACCTTCAG 
-1867/+262 
R: AGATCTTGTACTCGCTGATGGCAAAG 
63ºC 
   
F: ACGCGTCACAGGTGTGGACAAAGTGG 
-1128/+262 
R: AGATCTTGTACTCGCTGATGGCAAAG 
63ºC 
   
F: ACGCGTTCCAGGAGCTTCCTCTTCCT 
-650/+262 
R: AGATCTTGTACTCGCTGATGGCAAAG 
62ºC 
   
F: ACGCGTGAATCCAGAGTGAGCCAAGC 
-251/+262 
R: AGATCTTGTACTCGCTGATGGCAAAG 
62ºC 
AT: annealing temperature 
 
 
4.2 Oligonucleotides for cystatin D mutants 
Table IV. 
Primers Sequence AT 
F: CCAGATCAATGAAGTTCCCGGGGGAGGATAAAATTTCCATTC 
W108G 
R: GAATGGAAATTTTATCCTCCCCGGGAACTTCATTGATCTGG 
55ºC 
   
F: CCTTGATGGTGGCCGTGGCCGGCATCCATGCCACAGACCCTC 
Δ1-12 R: GAGGTCTGTGGCATGGATGCCGGCCACGGCCACCATCAAGG 55ºC 
AT: annealing temperature 
 
 
4.3 Oligonucleotides for chromatin immunoprecipitation assay 
Table V. 
Primers Sequence AT 
F: CCACAGTGACGCTTGGTCTA 
CST5 -840/-571 
R: GTCTGGGCAATAGAGCCGTA 
60ºC 
   
F: ATCTCCCAGAGAGCAAAGCA 
CST5  (negative control) 
R: GAATCCAGAGTGAGCCAAGC 
58ºC 
   
F: CGTTTCCTCCTGTCCCTCTC 
CYP24 -665/-380 
R: TGCCTTCCTGGGGGTTATCTC 
60ºC 
AT: annealing temperature 
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4.4 Oligonucleotides for RT-PCR 
Table VI. 
Primers Sequence AT 
F: TCTGGGATTGTACCGCAGC 
TBP 
R: CGAAGTGCAATGGTCTTTAGG 
59ºC 
   
F: TGGGAACAAGAGGGCATCTG 
SDHA 
R: CCACCACTGCATCAAATTCATG 
59ºC 
   
F: ATTTGGGTCGCGGTTCTTG 
UBC 
R: TGCCTTGACATTCTCGATGGT 
59ºC 
   
F: AGAACGCATTGCCACATACACTC 
CDH1 
R: CATTCTGATCGGTTACCGTGATC 
60ºC 
   
F: CACTATGCCGCGCTCTTTC 
SNAI1 
R: GGTCGTAGGGCTGCTGGAA 
68ºC 
   
F: GGCAAGGCGGTTTTCCAGAC 
SLUG/SNAI2 
R: GCTCTGTTGCAGTGAGGGC 
59ºC 
   
F: CATGTCCGCGTCCCACTAG 
TWIST 
R: TGTCCATTTTCTCCTTCTCTGG 
59ºC 
   
F: GCCAATAAGCAAACGATTCTG 
ZEB1 
R: TTTGGCTGGATCACTTTCAAG 
55ºC 
   
F: TATGGCCTACACCTACCCAAC 
ZEB2 
R: AGGCCTGACATGTAGTCTTGTG 
59ºC 
   
F: CCTCTGCAGGTGATGGCTG 
CST5 
R: GGACTTGGTGCATGTGGTTC 
61ºC 
   
F: CGAAGAGGAAGGCGATTTAG 
LEF1 
R: GTCTGGCCACCTCGTGTC 
60ºC 
AT: anealing temperature 
 
5. Plasmids  
For transactivation assays two different types of constructs were used: reporter plasmids and 
expression vectors. The reporter plasmids have the cDNA of a reporter gen controlled by the 
promoter of interest. Those used in this work have the Firefly luciferase reporter gene under 
the control of the following DNA fragments: four copies of VDRE upstream of a minimal 
herpes simplex timidine kinase (tk) promoter (4xVDRE-tk-Luc, provided by Dr. C. Carlberg, 
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University of Kuopio, Finland); three copies of wild type (TOP-flash) or mutated (FOP-flash) 
TCF/LEF-1 binding sites upstream of a minimal c-fos promoter (a gift from Dr. H. Clevers, 
Utrecht, The Netherlands); four copies of wild-type (4xCBF1wt-Luc) or mutated (4xCBFmut-
Luc) CBF1 binding sites upstream of a luciferase gene (provided by Dr. Diane Hayward, 
John Hopkin´s University, Maryland, USA); the -987/+92 human CDH1 promoter fragment 
(provided by Dr. A. García de Herreros, Institut Municipal d’Investigació Mèdica, Barcelona); 
the -266/+352 and -96/+352 human c-MYC promoter fragments (P1P2myc-Luc and P2myc-
Luc, respectively, provided by J. León, Universidad de Cantabria, Santander); the -
1876/+262, -1128/+262, -650/+262, -251/+262 fragments of CST5 promoter (described in 
section 7). As internal control of transfection efficiency, pRLTK (Promega) containing a 
Renilla reniformes (RLuc) reporter gene controlled by tk promoter was used. 
For ectopic protein expression, we used expression vectors in which a strong promoter 
drives the transcription of the cDNA of interest. The expression vectors used were: human 
VDR (provided by Dr. M. Zenke, University of Aachen, Germany) or a truncated VDR lacking 
the eleven carboxy-terminal amino-acids (ΔAF2, donated by Prof. Ana Aranda from our 
Institute), both in pSG5, and cystatin D in pcDNA3.1 (described in section 7). Three different 
cystatin D mutants, with reduced antiproteolytic activity, all in pcDNA3.1, were also used 
(described in section 7). 
 
6. In silico analysis of the human CST5 gene promoter   
The sequence of the human CST5 gene was obtained from EMSEMBL database. The 
presence of putative VDR binding sites in a sequence of 2 Kb before the transcription start 
site and the first exon was examined.  The effect of variation of every single nucleotide 314 in 
comparison with the consensus DNA binding motif, sequence RGKTCA (R = A/G, K = G/T 
and D = A/G/T), was considered. DR3 and DR4 consensus sites or those with one different 
nucleotide from consensus were looked up. Moreover, the conservation of these putative 
sites in other species was carried out using the USCS genome Browser database (in Macaca 
mulatta genome). 
 
7. DNA cloning and mutagenesis   
Several fragments of the CST5 promoter (-1867/+262, -1128/+262, -650/+262, -251/+262) 
were amplified by PCR using genomic DNA from SW480-ADH cells as template and the 
high-fidelity Pfx DNA polymerase (Invitrogen). The forward and reverse primers used are 
described in section 4.1. The resulting products were cloned into the pCRII-TOPO vector 
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(Invitrogen) and sequenced. Subsequently, they were subcloned as Mlu/BglII fragments into 
the promotorless pGL3basic Firefly luciferase (Luc) expression vector (Promega). 
pcDNA3.1-CST5 plasmid was obtained by subcloning the full-length human CST5 cDNA 
from the pEMBL19 plasmid (provided by Prof. Carlos López Otín, Universidad de Oviedo, 
Asturias) by digestion with EcoRI and XbaI. 
Directed mutagenesis of CST5 cDNA was carried out using Quick Change® Site Directed 
Mutagenesis kit (Stratagene) according to the manufacturer’s guidelines. For this purpose, 
forward and reverse primers (described in section 4.2) were designed containing the desired 
point mutation (W108G) or deletion (Δ1-12) in the middle of the primer sequence. The 
primers were extended by PCR using the high-fidelity Pfu DNA polymerase (Promega).  The 
mutations consisted in changing the Trp (TGG) in position 108 for a Gly (GGG) in the point 
mutation, and the deletion of the first 12 amino acids (shown in Figure 34). For the single 
CST5 W108G mutant the pcDNA3.1-CST5 was used as template. For the double CST5 
W108G/Δ1-12 mutant the pcDNA3.1-CST5 W108G mutant was used as template. The PCR 
reactions were digested with DpnI restriction enzyme (Stratagene) to digest the parental 
DNA. Plasmids were subjected to DNA sequencing to verify the mutation and fidelity of the 
whole cDNA sequence. 
 
8. Luciferase expression analysis 
  
For transient transactivation assays, cells cultured in 24-well dishes were transfected in 
triplicate using the jetPEI™ transfection reagent (PolyPlus Transfection). Transactivation 
assays contained 20 ng of RLuc expression vector pRLTK, 200 ng of Luc promoter reporter 
and the indicated quantities of expression vectors in each case. The amount of total DNA 
transfected in every point of each experiment was made equal with pcDNA3 (Invitrogen).  If 
necessary, 24 h post-transfection the cells were changed into a charcoal-treated serum-
containing medium and treated with 1α,25(OH)2D3 or vehicle. After 48 h of transfection or 
treatment with the hormone, depending on the experiment, Luc and RLuc activities were 
measured using Dual Luciferase™ Reporter Assay System and a Glomax 96-microplate 
Reader luminometer (both from Promega). Luc activity was normalized to the RLuc activity 
(Luc/RLuc). Mean values and standard deviations of triplicates were calculated. All the 
experiments were performed at least three times. 
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9. Generation of cells stably expressing wild type or mutant CST5  
SW480-ADH, LS174T and HCT116 cells stably expressing cystatin D were generated by 
transfection with pcDNA3.1-CST5, pcDNA3.1-CST5 W108G, pcDNA3.1-CST5 W108G/Δ1-12 
or pcDNA3.1 plasmids (control, mock), using jetPEI™ transfection reagent (PolyPlus 
Transfection), followed by selection with 0.5 mg/ml (SW480-ADH and LS174T) or 2 mg/ml 
(HCT116) G418 (Sigma) for two or four weeks. Each single antibiotic resistant clone was 
isolated using cloning cylinders. Cystatin D expression was verified by western blot. 
 
10. Gene silencing  
To knock-down CST5 expression SW480-ADH cells were seeded in 35 mm dishes and 
infected with lentiviral particles containing a U6 promoter driving a short hairpin RNA 
(shRNA) targeting the respective RNA. Mission® TRC shRNA (Sigma) lentiviral particles 
against human CST5 or scramble negative control were used. After infection the cells were 
treated with 1 µg/µl puromycin (Sigma). The transfection efficiency was estimated using in 
parallel lentiviral particles codifying the TurboGFP gene (clone SHC003; Sigma).  Control 
cells were infected with lentivirus bearing a non-targeting shRNA that activates the RISC 
complex and the RNA interference (RNAi) pathway but that contains at least five mismatched 
nucleotides compared with any human gene (clone SHC002; Sigma). 
 
11. Total RNA extraction and quantitative RT-PCR  
Total RNA was isolated with the RNeasy Kit (Qiagen). The extracted RNA was analyzed 
electroforetically using 1% agarose gels and stained with SYBR® Safe DNA gel stain 
(Invitrogen) and was quantified with NanoDrop® ND-1000 Spectrophotometer (NanoDrop 
Technologies). 
Cellular RNA levels of CST5, SNAI1, SNAI2, TWIST, ZEB1, ZEB2, CDH1 and LEF-1 were 
quantified by real-time RT-PCR. The level of CYP24 RNA was measured in relation to that of 
18S rRNA using the comparative CT method and RNA TaqMan probes (Applied Biosystems) 
according to the manufacturer’s guidelines and described previously 237, using the 7900HT 
Fast Real-Time PCR System (Applied Biosystems).  
For the synthesis of the first strand of cDNA, 400 ng of total RNA were retro-transcribed 
using the GeneAmp® Gold RNA PCR Core Kit (Applied Biosystems) that use the MultiScribe 
(Murine Leukemia Virus) Reverse Transcriptase and random hexamers as primers. The 
reaction was performed in a Light-Cycler apparatus using the LightCycler-FastStart DNA 
Master SYBR Green I Kit (both from Roche). The final volume in each reaction was 20 µl that 
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included 2 µl of the retro-transcription product, 0.5 µl of each primer and 1x reaction mix 
containing FastStar DNA polymerase, reaction buffer, dNTPs and SYBR Green. Thermal 
cycling for all genes was initiated with a denaturation step of 95ºC for 10 min and consisted 
of 40 cycles (denaturation at 94ºC 0 s, specific annealing temperature showed in section 4.4 
for 5 s, and elongation at 72ºC for 5 s). At the end of each cycle the fluorescence acquisition 
was made. All the measurements were made in triplicate. At the end of the PCR cycles, 
melting curve analyses were performed as well as electrophoresis of the products on non-
denaturing 8% polyacrylamide gels, followed by sequencing, in order to validate the 
generation of the specific PCR product expected. 
The relative concentration of the target and the reference genes was calculated by 
interpolation on a standard curve for each gene generated with a serial dilution of cDNA 
obtained from SW480-ADH cells. Values were normalized versus the geometric average of 
three control housekeeping genes: TBP (TATA binding protein), SDHA (succinate 
dehydrogenase complex subunit A) and UBC (ubiquintin C) as described 308. 
The sequences of the oligonucleotides used as primers in the quantitative PCR are shown 
in section 4.4. In all cases the forward and reverse primers were designed in different exons 
to avoid the genomic DNA amplification that could be contaminating the RNA sample.  
The quantitative RT-PCR experiments were performed in collaboration with Dr. F. Bonilla’s 
group from Hospital Universitario Puerta de Hierro, Madrid. 
 
12. Oligonucleotide microarrays  
The gene expression patterns of two different clones of HCT116 CST5 and mock cells as 
well as HCT116 wild-type cells were analyzed using oligonucleotide microarrays (GeneChip 
Human Gene 1.0 ST Array, Affymetrix). This microarray is designed to measure the gene 
expression of well-annotated genes, using a single probe set per gene comprised of multiple 
probes that are distributed along the entire length of the genomic locus. Each of the 28,869 
genes is represented on the array by approximately 26 probes spread across the full length 
of the gene. Before the study with microarrays, the expression levels of CST5 were analyzed 
by quantitative RT-PCR (described in the previous section) to guarantee the good conditions 
of the cells and to use them as a control for the future results. 
The microarray hibridation as well as the initial processing of data set were performed by 
the Unidad de Genómica y Proteómica, Centro de Investigación del Cáncer, Salamanca. 
First, the RNA samples were analyzed with the 2100 Bioanalyzer (Agilent Technologies) to 
corroborate their quality. Subsequently, 4.4 µg of RNA from each sample were used to 
synthesize the double strain cDNAs using the SuperScript Double Stranded cDNA Synthesis 
Kit (Invitrogen). After their purification, the RNA polymerase T7 in presence of biotinylated 
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nucleotides (BioArray High Yield RNA Transcript Labeling Kit, Enzo Life Science) was used 
in vitro for the transcription of the cDNAs. The biotinylated cRNAs were purified and 
fragmented to their subsequently microarray hibridization.  A fraction of each cRNA was 
hybridized with a GeneChip Test3 Array (Affymetrix) to verify the label quality.  If a favorable 
result was obtained, each cRNA was hybridized with a GeneChip Human Gene 1.0 ST Array 
at 45ºC overnight. Later, the microarray was washed and labeled with phycoerythrin-
streptavidin and the result was digitalized with a fluorescence scanner. 
The fluorescence data were analyzed by the Unidad de Bioinformática, Centro de 
Investigación del Cáncer, Salamanca. Robust microarray analysis algorithm was used for 
background correction, intra- and inter-microarray normalization, and expression-signal 
calculation 31,130,131. Once calculated, the absolute expression signal for each gene (the 
signal value for each probe-set) in each microarray, significance analysis of microarrays 
method 301, was applied to calculate significant differential expression and find the gene 
probe-sets that characterized the samples of each compared state. The method uses 
permutations to achieve robust statistical inference of the most significant genes and 
provides P values adjusted to multiple testing using false discovery rate 301. A cutoff of false 
discovery rate < 0.05 was used for all the differential expression calculations. Finally, the 
resulting lists of candidate genes were tested using another algorithm, the so-called global 
test 93, which reveals the group of genes that has a global expression pattern most 
significantly related to the clinical feature studied. We applied all these methods using R and 
Bioconductor. 
The comparison of HCT116 CST5 vs HCT116 Control candidate genes generated a group 
of genes downregulated or upregulated by cystatin D overexpression. The classification of 
differentially expressed genes was carried out filtering the data to include only the transcripts 
which expression differs at least 1.5-fold between the compared samples.  
For functional classification of regulated genes we used Gene Ontology annotations and 
the information available in the NCBI Gene database (http://www.ncbi.nlm.nih.gov 
/sites/entrez?db=gene). 
 
13. Microarrays validation by quantitative RT-PCR 
  
Validation of selected genes from microarrays data was performed in the Unidad de 
Genómica del Parque Científico de Madrid.  
Total RNA was isolated as previously described in section 11. Cellular RNA levels were 
measured using the following Taqman probes (Applied Biosystems): 18S rRNA 
(Hs99999901_s1), GAPDH (Hs99999905_m1), MAL2 (Hs00294541_m1), MEF2C 
(Hs00231149_m1), AP1M2 (Hs00194014_m1), RUNX2 (Hs00231692_m1), ID3 
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(Hs00171409_m1), TMPRSS4 (Hs00212669_m1), NAV3 (Hs00372108_m1), NT5E 
(Hs01573922_m1), VCAN (Hs00171642_m1), WNT16 (Hs00365138_m1), ANX3 
(Hs00192982_m1), and RUNX1 (Hs01021970_m1). 
For the synthesis of the first strand of cDNA, 10 ng/µl of total RNA were retro-transcribed 
using the Applied High Capacity Transcription kit (Applied Biosystems) that use the 
MultiScribe (Murine Leukemia Virus) Reverse Transcriptase and random hexamers as 
primers. The reaction was performed using the 7900HT Fast Real-Time PCR System 
(Applied Biosystems). The final volume in each reaction was 10 µl that included 0.5 µl of the 
retro-transcription product, 0.5 µl of each primer and 250 nM TaqMman probe containing 
FAM-labeled, MGB-NFQ modified (Applied Biosystems). Thermal cycling for all genes 
consisted of 2 min at 50ºC, 10 min at 90ºC and 40 cycles (denaturation at 95ºC for 15 s, and 
elongation at 60ºC for 1 min). All the measurements were made in triplicate.  
Data were analyzed using the Sequence Detection System software (Applied Biosystems) 
and relative RNA levels were calculating using the comparative CT method as recommended 
by Applied Biosystems 178. 
 
14. Chromatin immunoprecipitation (ChIP) assays  
For chromatin immunoprecipitation assays, the described protocol in the Chromatin 
Immnunoprecipitation (ChIP) Assay Kit (Upstate) with some modifications 260 was used. 
Subconfluent cultures of SW480-ADH cells were synchronized with α-amanitin (2.5 µM) in 
serum-free medium for 2.5 h at 37ºC. After this, cells were rinsed twice in phosphate-
buffered saline (PBS) and treated with 1α,25(OH)2D3 or vehicle during 30 min, 1 or 4 h. Cells 
were fixed by 15 min of incubation in medium containing 1% of formaldehyde at 37ºC. 
Subsequently, cells were lysed in an appropriated volume of Lysis Buffer (50 mM TrisHCl pH 
8, 10 mM EDTA and 1% SDS plus protease inhibitor cocktail) and chromatin was sheared in 
a bath sonicator (Diagenode Bioruptor), to an average length of 0.2-1.5 kb. Samples were 
then centrifuged at 13,000 rpm for 10 min at 4ºC, and the supernatant containing the 
fragmented chromatin were collected. Two hundred µg of fragmented DNA per antibody and 
condition (including a no-antibody control sample) were diluted in 10x Dilution Buffer (16.7 
mM Tris-HCl pH 8.1, 167 mM NaCl, 1.2 mM EDTA, 1.1% Triton X-100 and 0.01% SDS), pre-
cleared for 1 h at 4ºC with 60 µl of a 50% slurry Salmon Sperm DNA/protein G-Sepharose 
(Upstate), and incubated overnight at 4ºC with antibodies against VDR, SMRT (both from 
Santa Cruz Biotechnology) histone H4 (acetyl K12) (Upstate) or rabbit IgG (Santa Cruz 
Biotechnology). Thirty µg of each sample (input) were frozen and kept at -80ºC until the 
reverse-crosslink step. After 14 h at 4ºC in a rotating platform, samples were incubated in 
presence of 60 µl of Salmon Sperm DNA-protein A/G Agarose 50% slurry for 1 h. Immune 
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complexes were eluted after two rounds of incubation with freshly prepared Elution Buffer 
(1% SDS, 0.1 M NaHCO3), and cross-linking was reverted by addition of 20 µl of 5 M NaCl 
and incubation at 65ºC for 4 h. After 1 h of proteinase K (Sigma) digestion, DNA was 
recovered by phenol/chloroform extraction and ethanol precipitation. For semi-quantitative 
PCR, reactions were performed in a range of amplification that varied from 35 to 38 cycles. 
The sequence of primers used in these assays is described in section 4.3. For each 
promoter, the PCR sensitivity was evaluated with input serial dilutions. Amplification products 
were analyzed by electrophoresis in 2% agarose gel and visualized by SYBR® Safe DNA gel 
stain (Invitrogen). 
 
15. Western blotting  
Whole-cell extracts were prepared by washing the monolayers twice in PBS and cell lysis by 
incubation in RIPA buffer (150 mM NaCl, 1.5 mM MgCl2, 10 mM NaF, 10% glycerol, 4 mM 
EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 50 mM Hepes pH 7.4) plus 
phosphatase- and protease-inhibitor mixture (25 mM β-glycerophosphate, 1 mM Na3VO4, 1 
mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin) for 15 min on ice followed by 
centrifugation at 13,000 rpm for 10 min at 4ºC. Protein concentration was measured using 
the Bio-Rad DC protein assay kit (Bio-Rad). Analysis of cell lysates or immunoprecipitates 
was performed by electrophoresis in SDS gels and protein transfer to PVDF Immobilon-P 
membranes (Millipore). The membranes were incubated with blocking solution (5% BSA in 
TBS 0.1% Tween-20) at room temperature (R/T) and subsequently, with the appropriate 
primary antibodies prepared in blocking solution (indicated dilutions in section 3) at 4ºC 
overnight. Finally, the membranes were incubated with the secondary HRP-conjugated 
antibodies diluted in blocking solution as indicated in section 3 for 1 h at R/T and the 
antibody binding was visualized using the ECL detection system (Amersham-G.E. 
Healthcare). The images were acquired with a SNAPSCAN e42 (AGFA) and were quantified 
with the ImageJ program. In all cases, the shown picture and its quantification belong to a 
representative experiment of at least three performed. 
 
16. Immunofluorescence and confocal microscopy  
Cells were plated in 60 mm or 24-well dishes previously covered with 10 mm diameter cover 
glasses. At the end of the experiment cells were rinsed once in PBS and fixed in 3.7% 
formaldehyde for 10 min at R/T. The cells were permeabilized in 0.2% Triton X-100 for 10 
min at R/T. Non-specific sites were blocked by incubation with PBS containing 1% DifcoTM 
Skim Milk (BD) for 10 min at R/T before incubating the cells with the appropriated primary 
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antibodies diluted in PBS for 1 h at 37ºC. After four washes in PBS, the cells were incubated 
with secondary antibodies for 45 min at R/T, washed three times in PBS and mounted in 
VectaShield (Vector Laboratories). Propidium iodide (PI) staining was done for 10 min at R/T 
and followed by four washes in PBS. Images were acquired with an Olympus DP70 digital 
camera mounted on a Zeiss Axiophot microscope equipped with epifluorescence and 
confocal images were captured with a Leica TCS SP2 confocal microscope. For double 
labeling experiments, images of the same confocal plane were generated and superimposed. 
Phase-contrast images were captured with a Leica DC300 digital camera mounted on an 
inverted Leitz Labovert FS Microscope. All the images were processed using Adobe 
Photoshop CS2 software. 
The specific primary and secondary antibodies used in these experiments are shown in 
section 3. 
 
17. Flow cytometry  
Cells were synchronized by 17 h incubation with 2.5 mM thymidine (Sigma) in McCoy’s 5A 
medium. Later, they were washed twice in PBS and incubated in normal medium for 
additional 6 h at 37ºC to release them from the cell cycle blockade. To increase the 
proportion of G1-arrested cells, cultures were then treated with 0.5 mM L-mimosine (Sigma) 
for 20 h. At various timepoints the cells were washed in PBS containing 50 mM EDTA, 
trypsinized, resuspended in 1 ml PBS/EDTA and fixed by addition of 3 ml ice-cold 100% 
ethanol and left overnight at 4 ºC. Fixed cells were then pelleted and washed in 1 ml 
PBS/EDTA, and DNA was stained with 0.025 mg/ml PI (Sigma) in PBS/EDTA containing 
0.05% NP40 and 5 ng/µl RNase A. The fraction of the population in each phase of the cell 
cycle was determined as a function of DNA content using the FACScan flow cytometer FC 
500 MPL (Beckman Coulter) equipped with MXP software. 
 
18. Preparation of conditioned media   
Cells from 80% confluent 100 mm dishes were washed twice in PBS and incubated in 
serum-free medium during 48 h. The supernatant were collected and after 10 min 
centrifugation at 2,000 g were concentrated 100x using Amicon Ultra-15 and Microcon YM-
10 centrifugal filter units (Millipore Corporation).  
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19. Cathepsin L activity assays  
Cathepsin L activity was assessed using fluorigenic substrate Z-Phe-Arg-AMC 
(Benzyloxycarbonyl-Phe-Arg-7-amino-4-methylcoumarin; Bachem) in the presence of E-64 
(Sigma), a broad spectrum inhibitor of cysteine proteases, and CA-074 (Bachem), a specific 
inhibitor of cathepsin B, by using the Inubushi method 128 with some modifications. Whole-cell 
extracts were prepared by lysis in cathepsin L lysis buffer (400 mM sodium phosphate buffer 
pH 6, 75 mM NaCl, 4 mM EDTA, 0.25% Triton X-100), incubated 1 h on ice and 
homogenized by sonication. Twenty mmol substrate was incubated with the whole-cell 
extracts in the cathepsin L assay buffer (100 mM sodium acetate buffer pH 5.5, 1 mM EDTA, 
2 mM DTT) in the presence of 50 mmol E-64 or CA-074 at 37 ºC for 10 min. The amount of 
7-amino-4-methylcoumarin (AMC) liberated from the substrate was monitored 
fluorometrically with excitation at 370 nm and emission at 480 nm. Total cysteine peptidase 
activity was determined as the difference between the total activity and the background 
activity of the non-cysteine peptidases determined by using E-64. Cathepsin L-like activity 
was measured by inhibiting cathepsin B activity with CA-074. As positive control, 
recombinant human cystatin D protein (R&D Systems) was used. 
 
 
20. Cell proliferation assay  
To measure proliferation, the cells (8 x 103) were seeded in 24-well plates. After 5 days they 
were washed once with PBS and living cells were counted after trysinization. In certain 
experiments the cells were treated for up to 5 days with 100 nM of 1α,25(OH)2D3 or vehicle. 
Alternatively, [3-(4,5-dimethythiazol-2-yl)-2,5-diphenyl] tetrazolium bromide (MTT) assays 
(Roche Diagnostics) were used. The assay is based on the cleavage of the yellow 
tetrazolium salt MTT to purple formazan crystals by metabolic active cells. Cells were seeded 
in 24-well plates. At indicated times, cells were incubated with the MTT solution (final 
concentration of 0.5 mg/ml) for approximately 4 h at 37ºC. After this incubation period, a 
water-insoluble formazan dye is formed. After solubilization with 500 µl of 0.04 M HCl 
isopropanol during 30 min at R/T, the formazan dye was quantitated using a scanning 
microplate spectrophotometer (VersaMax, Molecular Devices). The absorbance was 
measured as 570nm-630nm. All experiments were performed at least three times using 
triplicates.  
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21. Migration assays 
  
The migratory capacity of HCT116 cells transfected with pcDNA3.1-CST5 or empty vector 
was analyzed using 8.0 µm pore Transwells® (Corning Inc.). Cells were resuspended in 200 
µl of serum-free medium (final concentration of 150,000 cells/ml) and added to the upper 
side of the Transwell®. At this point, in some experiments, recombinant human cystatin D 
protein (R&D Systems) or E-64 (Sigma) were added to the resuspended cells medium (at the 
indicated concentrations). The lower chamber was filled with 600 µl of 20% FBS DMEM or 
conditioned media from tumor cells. After 24 h incubation, cells attached to the lower surface 
of the filter were stained using Diff-Quick (Dade Behring) and counted (10 fields/Transwell®) 
using an inverted Leitz Labovert FS Microscope. Experiments were performed at least three 
times using duplicates.  
 
22. Anchorage-independent growth assays 
  
HCT116 cells (5 x 103) transfected with an empty vector or pcDNA3.1-CST5 were trypsinized 
and suspended in 1.5 ml of 0.35% Difco Noble agar in DMEM containing 10% FBS. The 
agar-cell mixture was plated on top of a bottom layer of 0.5% agar (1.5 ml per well in 6-well 
plates). Plates were incubated at 37ºC in humidified incubator for 14 days. After this time, 
plates were stained with 0.5 ml of 0.001% Crystal Violet for more than 1 h and viable 
colonies larger than 50 µm were scored. The experiment was performed in triplicate for each 
cell line. 
 
23. Xenograft tumor growth   
For these assays severe immunodeficient female scid mice (B6;CB17-Ghrhrlit Prkdcscid/BM, 
The Jackson Laboratories) were used. These mice lack functional T or B-lymphocytes, and 
tumors from other species are easily transplanted and grow without being rejected. HCT116 
or LS174T cells expressing empty vector (mock) or two different clones of pcDNA3.1-CST5 
(CST5) were used in these assays. For each cell line, mice were subcutaneously injected 
with 3 x 106 mock or CST5 cells, resuspended in 200 µl of PBS, in left and right flank, 
respectively. Tumor size was measured 3 times per week by using the ellipsoid volume 
formula (0.5 x L x W x H) where L, W and H are the tumor length, width and height (in cm), 
respectively. Animals were euthanized when their external tumor diameter reached 1.5 cm. 
The maintenance and handling of animals were as recommended by the European Union 
(ECC Directive of November 24th, 1986, 86/609/EEC) and all experiments were approved by 
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the Animal Experimentation Committee of our Institute. Every effort was made to minimize 
animal suffering and to reduce the number of animals used. 
 
24. Immunohistochemistry 
  
Human tissues were obtained as formalin-fixed, paraffin-embedded tissue sections from the 
archives of the tumor bank from the Hospital Universitario Central de Asturias, Oviedo. They 
were made anonymously according to the guidelines approved by the Research Ethics 
Board of the Hospital. Tissue arrays containing a total of 51 samples including three 
replicates representing different locations were used to evaluate cystatin D and VDR 
expression according to the differentiation status. After dewaxing and rehydrating, samples 
were blocked in 15% goat serum and then incubated overnight at 4ºC with anti-cystatin D 
(1:1,000) or anti-VDR antibody (1:150). Visualization of specific interactions was monitored 
by using the EnVision HRP System (DAKO, Copenhagen, Denmark) following the 
manufacturer’s instructions, and the staining was completed by incubation with 
diaminobenzidine colorimetric reagent (DAKO), followed by counterstaining with hematoxylin. 
Finally, the slides were dehydrated and mounted. Controls included samples that were 
incubated with a preimmune serum. Normal parotid tissue was used as positive control for 
cystatin D. Protein expression was graded independently by two observers as either very 
high (+++), high (++), moderate (+), low (+/-) or negative (-) depending on the level of 
epithelial staining. 
Formalin-fixed, paraffin-embedded tissue sections from tumors generated by SW480-ADH 
cells in immunodeficient mice that were treated with EB1089 (100 nM) or placebo 226 were 
immunostained following the previously described protocol. 
This study was performed in collaboration with Dr. Aurora Astudillo and Marta S. Pitiot 
from the Hospital Universitario Central de Asturias, Oviedo. 
 
25. Quantification of protein expression in human samples  
Tissue protein from normal and tumor tissue samples (described in section 2) was extracted 
by pulverizing the samples in liquid nitrogen using a mortar and homogenization using a 
Potter-Elvehjem apparatus in lysis buffer (50 mM Tris-HCl pH 7.5, 1% NP-40, 0.25% sodium 
deoxycholate, 150 mM NaCl, 2 mM MgCl2, 1 mM EDTA, 10% glycerol, 0.5 mM DTT and 
protease and phosphatase inhibitor mix) on ice. After 20 min centrifugation at 13,000 rpm, 
the expression level of cystatin D, VDR and E-cadherin proteins was analyzed by western 
blotting. 
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26. Statistical analysis   
The data are expressed as the mean ± standard deviation (SD) unless otherwise specified. 
Statistical significance was assessed by two-tailed unpaired student’s t-test. The single 
asterisk indicates P < 0.05, the double asterisk P < 0.01, and the triple asterisk P < 0.001. 
When P > 0.05, the data were considered not significant (ns). All statistical analyses were 
performed using SPSS 13.0 statistical software (SPSS Inc., Chicago, IL). As the 
tumor/normal tissue (T/N) ratios of VDR and cystatin D expression were not normally 
distributed (Kolmogorov-Smirnov test, Lilliefors correction), the data distribution was 
normalized using log2 for statistical analysis 226. The geometric (rather than the arithmetic) 
average of the T/N ratio was used. Correlations between protein expression levels were 
analyzed using the Spearman correlation coefficient. In addition, cystatin D protein 
expression was divided in two groups, low and high expression, according to the median 
value of this variable and the expression of VDR and E-cadherin in these two groups was 
represented in a box-plot graphic. The comparison between the two groups of data was done 
using the Kruskal-Wallis test.  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1. 1α ,25(OH)2D3 increases cystatin D RNA and protein expression  
Previous studies of our group analyzing the gene expression profile induced by 
1α,25(OH)2D3 in SW480-ADH colon cancer cells showed the regulation of around 250 genes 
(227 and unpublished data). Approximately, two thirds of these genes are upregulated by the 
hormone, while one third are inhibited. One of the 1α,25(OH)2D3-upregulated genes is CST5, 
that encodes cystatin D, whose RNA levels increased 3.73-fold after 4 h of treatment.   
 
Figure 10. 1α,25(OH)2D3 induces cystatin D expression in SW480-ADH cells. (A) Kinetics of CST5 RNA (top) 
and protein (bottom) induction by 1α,25(OH)2D3. SW480-ADH cells were incubated with 1α,25(OH)2D3 (100 nM) 
or vehicle for the indicated times, and the levels of CST5 RNA and protein were measured by quantitative RT-
PCR (top) or western blot (bottom) as explained in Methods. Normalized mean values and SD obtained in three 
independent experiments are shown. (B) Dose-curve induction of CST5 RNA (top) and protein (bottom) by 
1α,25(OH)2D3. (C) Lysates of cells treated with 1α,25(OH)2D3 (100 nM) for 48 h were analyzed by western blot 
with antibodies against cystatin D or cystatin SN. (D) Conditioned media of cells treated or not with 1α,25(OH)2D3 
(100 nM) for 24 or 48 h were analyzed by western blot with antibodies against cystatin D or cystatin C. Numbers 
between the blots correspond to mean of the fold increase values obtained in two experiments. 
 
To validate the upregulation of CST5 by 1α,25(OH)2D3 we performed quantitative RT-PCR 
and western blot analyses. Kinetics analyses of the cellular RNA and protein content 
following 1α,25(OH)2D3 addition (100 nM) showed increased CST5 RNA and protein level 
with a gradually increase, reaching around 60- and 30-fold, respectively, at 48 hours post-
treatment (Figure 10A). This effect was dose-dependent and physiological concentrations 
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(10 and 1 nM) of 1α,25(OH)2D3 caused 2.8- and 10.4-fold-increase of protein expression 
level, respectively. Similar results were observed at RNA level (Figure 10B). The induction of 
cystatin D by 1α,25(OH)2D3 was specific, as no induction of cystatin SN was found (Figure 
10C). We also analyzed if 1α,25(OH)2D3 regulated the amount of secreted cystatin D in the 
medium. Indeed, the level of secreted cystatin D protein increased slightly at 24-48 hours 
post-treatment (2-fold; Figure 10D), while no change in cystatin C was observed. Next, we 
examined if 1α,25(OH)2D3 upregulates cystatin D in other colon cancer cell lines. By 
quantitative RT-PCR we found an induction of cystatin D expression in Caco-2, LS174T, 
Colo205, and HCT116 cells in good correlation with the activation of a consensus VDRE 
(Figure 11A and 11B). 
 
Figure 11. 1α,25(OH)2D3 induces cystatin D expression in several human colon cancer cell lines. (A) 
Normalized level of CST5 RNA in CaCo-2 (left), LS174T (middle left), Colo205 (middle right) and HCT116 (right) 
cells treated with 1α,25(OH)2D3 (100 nM) for the indicated times as estimated by quantitative RT-PCR. (B) 
Ligand-activation of a consensus vitamin D response element in CaCo-2, LS174T, Colo205 and HCT116 cells. 
Cells were transfected with the 4xVDRE-DR3-Tk-Luc contruct and 24 h later were incubated with 1α,25(OH)2D3 
(100 nM) or vehicle for additional 48 h. Values correspond to luciferase induction by 1α,25(OH)2D3 in three 
independent experiments done in triplicate. (C) Immunofluorescence analysis of cystatin D induction. Images of 
SW480-ADH (left), HCT116 (middle) and SW480-R (right) cells treated with 1α,25(OH)2D3 (100 nM) or vehicle for 
48 h. The relocalization of β-catenin was analyzed as control of 1α,25(OH)2D3 action. Scale bars: 20 µm. 
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The increase in cystatin D protein was confirmed by immunofluorescence studies, which 
also showed a predominant localization of cystatin D in the cytoplasm of SW480-ADH cells 
treated with 1α,25(OH)2D3 (Figure 11C, left panel). The relocation of β-catenin from the 
nucleus and cytosol towards the plasma membrane was used as control of 1α,25(OH)2D3 
activity. This induction, although weaker than in SW480-ADH, was also observed in HCT116, 
whereas no cystatin D was detected in SW480-R cells that contain very low VDR levels and 
do not respond to 1α,25(OH)2D3 (Figure 11C, middle and right panels).  
To analyze whether the regulation of cystatin D expression takes place in vivo, we 
performed immunohistochemical analyses of tumors generated by SW480-ADH cells in 
immunodeficient mice that were treated with EB1089, a less calcemic 1α,25(OH)2D3 analog 
226. We analyzed several samples and performed the quantification of cystatin D expression 
by estimation of staining intensity as described in Materials and Methods section. In line with 
in vitro data, EB1089 treatment increased cystatin D expression, and thus, 80% of samples 
of mice treated with EB1089 showed high/very high staining level, whereas in control mice 
treated with placebo only 33.3% of samples were high/very high stained  (Figure 12). 
 
 
Figure 12. The 1α,25(OH)2D3 analog EB1089 induces cystatin D expression in vivo. (A) 
Immunohistochemical analysis of cystatin D expression in tumors generated by SW480-ADH cells in 
immunodeficient mice that were treated with EB1089 (100 nM) or placebo. Scale bar: 200 µm. (B) Quantification 
of cystatin D expression by estimation of staining intensity as described in Methods. The number of samples 
analyzed per group and the percentage corresponding to each level of cystatin D staining are shown.  
 
To assess the functionality of the cystatin D protein induced by 1α,25(OH)2D3 we studied 
the activity of its cathepsin targets in SW480-ADH cells (Figure 13). A series of enzymatic 
assays using specific substrates for two different cathepsins (L and B), showed that 
cathepsin L activity in extracts from 1α,25(OH)2D3-treated cells was lower (∼ 40%) than in 
those of vehicle-treated cells. Total cathepsin activity also decreased (∼ 50%), whereas that 
of cathepsin B, that is not inhibited by cystatin D, was unchanged by 1α,25(OH)2D3. 
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Recombinant cystatin D protein was used as control. No changes were found in total 
extracellular cathepsin activity (data not shown). 
 
 
Figure 13. Effect of 1α,25(OH)2D3 on cathepsin enzymatic activity. 1α,25(OH)2D3 inhibits cathepsin activity in 
SW480-ADH cells. Enzymatic assays for total cathepsin activity and for that of cathepsin L and cathepsin B in 
extracts from vehicle- and 1α,25(OH)2D3-treated cells were performed as described in Methods. Human 
recombinant cystatin D (hrCyst.D; 5 µg/ml) protein was used as control. Specific activity was expressed as 
relative fluorescence units (RFU). 
  
Altogether, these data validate the results obtained in the gene expression profile studies, 
and confirme cystatin D as a 1α,25(OH)2D3 target, not only in SW480-ADH cells but also in 
other colon cancer cell lines. 
 
2. 1α ,25(OH)2D3 induces cystatin D expression by direct activation 
of its gene promoter  
We next examined the mechanism by which 1α,25(OH)2D3 induced CST5 RNA and protein 
expression. For this reason we used the transcription and translation inhibitors actinomycin D 
and cycloheximide, respectively, in combination with 1α,25(OH)2D3 or vehicle (Figure 14). By 
quantitative RT-PCR we observed that the increase in CST5 RNA was abrogated by 
actinomycin D but not (P > 0.05) by cycloheximide, indicating a direct transcriptional effect of 
1α,25(OH)2D3.  
These results led us to study the effect of 1α,25(OH)2D3 on CST5 gene promoter. The in 
silico analysis of 2.1 kb (-1867/+262) CST5 gene promoter sequence allowed the 
identification of several putative VDR binding hemisites (consensus RGKTCA; R = A or G, K 
= G or T) that can be grouped in four (A to D) regions (Figure 15).  
 
 
 
RESULTS 
 
53 
 
Figure 14. Direct transcriptional effect of 1α,25(OH)2D3 on cystatin D expression. Quantitative RT-PCR 
analysis of CST5 RNA expression in SW480-ADH cells treated with 1α,25(OH)2D3 or vehicle that were pretreated 
for 30 minutes with (A) actinomycin D (2 µg/ml) or (B) cycloheximide (8 µg/ml) as indicated. 
 
To identify which hemisites could be responsible for 1α,25(OH)2D3 effect we generated 
four different fragments of the promoter (-1867/, -1128/, -650/ and -251/+262) containing 
one, five, seven or eight putative VDREs, respectively. These fragments were cloned by 
PCR into the pGL3 luciferase expression vector.  
 
 
 
 
 
Figure 15. Scheme of the proximal human CST5 gene promoter. Putative VDR binding site sequences and 
their position grouped in regions A-D are shown. 
 
 
Transactivation assays in SW480-ADH cells showed that, actually, 1α,25(OH)2D3 activates 
the CST5 promoter. Moreover, these assays revealed that most of the activation depends on 
the cluster of sites in region B (-650/-262) with no contribution of that in region A (Figure 16A, 
left panel). We also analyzed if this activation took place in other colon cancer cell lines. 
Indeed, CST5 promoter activation was also observed in LS174T and HCT116 cell lines but 
not in the VDR-deficient SW480-R or HEK293T cells (Figure 16B). However, the expression 
in HEK293T cells of an exogenous functional VDR led to an induction of CST5 promoter, 
similar to that observed in SW480-ADH cells (Figure 16A, right panel).  
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Figure 16. 1α,25(OH)2D3 directly activates the CST5 promoter. (A) Activation of CST5 promoter constructs by 
1α,25(OH)2D3 in SW480-ADH cells (left) and HEK293T cells cotransfected with an expression vector for wild-type 
VDR (right). (B) Activation of CST5  promoter by 1α,25(OH)2D3 in LS174T and HCT116 cells. VDR deficient 
SW480-R and HEK293T cells were used as negative control. Twenty-four hours after transfection, cells were 
treated with vehicle or 1α,25(OH)2D3 (100 nM) for an additional 48 h. The empty pGL3 vector was used as 
control. Values correspond to promoter induction by 1α,25(OH)2D3 in three independent experiments done in 
triplicate. 
 
In addition, experiments using SW480-R cells transfected with either wild-type VDR or the 
transcription activation-deficient VDRΔAF2 mutant assessed the requirement of a functional 
VDR for the activation of the CST5 promoter by 1α,25(OH)2D3 (Figure 17). These results 
show that 1α,25(OH)2D3 induces cystatin D expression at the transcriptional level. 
 To explore if the transcriptional activation of CST5 by 1α,25(OH)2D3 is mediated by a 
direct mechanism (implying the binding of VDR to its promoter), we performed chromatin 
immunoprecipitation (ChIP) assays (Figure 18). We used specific oligonucleotides that 
include the region B (-840/-571), and as negative control oligonucleotides including the 
region A (-63/+66).  Binding of VDR to the -840/-571 fragment was already observed at 30 
min after treatment with 1α,25(OH)2D3 and it was maintained after 4 h. No binding was 
detected to region A (data not shown). This event took place in parallel with the release of 
SMRT corepressor from the promoter and an increase in histone H4 acetylation, a marker of 
transcriptional activation. As a positive control we used CYP24, a target gene of 
1α,25(OH)2D3 that is induced directly by the binding of VDR to its promoter.  
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Figure 17. The activation of the CST5 promoter by 1α,25(OH)2D3 requires a transcriptionally competent 
VDR. SW480-R cells were cotransfected with the promoter construct pGL3-1867 or pGL3-251 and either the wild-
type VDR or the mutant ΔAF2-VDR (VDRΔAF2), or an empty vector. The cells were then treated with 1α,25(OH)2D3 
(100 nM) or vehicle for 48 h. As control the consensus 4xVDRE-DR3-Tk-Luc (VDRE) reporter construct was 
cotransfected with the wild-type or mutant VDR. Values correspond to promoter induction by 1α,25(OH)2D3 in 
three independent experiments done in triplicate. 
 
 
 
 
 
 
 
 
Figure 18. 1α,25(OH)2D3 induces VDR binding to and an active chromatin conformation of the CST5 
promoter in vivo. ChIP assay showing the induction by 1α,25(OH)2D3 of VDR binding, SMRT corepressor 
release, and increased histone H4 acetylation (AcH4) of the CST5 gene promoter in SW480-ADH cells. The 
CYP24 gene was used as control. The promoter regions studied are indicated. 
 
 
 
Altogether, these results show that CST5 is a direct transcriptional target of 1α,25(OH)2D3. 
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3. Acidic retinoids synergize with 1α ,25(OH)2D3 to enhance cystatin 
D expression  
Retinoids are structural and functional analogs of vitamin A. They are involved in the 
modulation of several biologic functions such as regulation of cell proliferation and 
differentiation, growth of bone tissue, immune function, and activation of tumor suppressor 
genes 280. Retinoids exert their pleiotropic effects through the interaction with nuclear 
receptors, defined as retinoic acid receptors (RARs) and retinoid X receptors (RXRs). These 
ligand-activated nuclear receptors induce the transcription of target genes by binding to 
retinoic acid (RA) responsive elements (RAREs) present in promoter regions. RARs and 
RXRs are also capable to interact with other nuclear receptors, and thus RARs can 
heterodimerize with RXRs, while RXRs heterodimerize with other nuclear receptors, 
including the thyroid hormone receptor (TR), vitamin D receptor (VDR), and peroxisomal 
proliferator activated receptor (PPAR), among others 42. 
 
 
 
Figure 19. Acidic retinoids potentiate 1α,25(OH)2D3 induction of cystatin D expression. (A) Activation of 
CST5 promoter construct by DHA or 9cRA alone or in combination with 1α,25(OH)2D3 in SW480-ADH cells. The 
cells were transfected with the promoter construct pGL3-650 or an empty vector. Twenty-four hours after 
transfection, cells were treated with vehicle, 1α,25(OH)2D3 (100 nM), DHA (100 nM), 9cRA (100 nM) or a 
combination of DHA or 9cRA with 1α,25(OH)2D3 for and additional 48 h. Values correspond to promoter induction 
in three independent experiments done in triplicate. (B) Lysates of cells treated during 48 h with DHA, 9cRA or 
1α,25(OH)2D3 at the indicated concentrations and combinations were analyzed by western blot.  (C) Western blot 
showing changes in cystatin D protein in SW480-ADH cells treated with 1α,25(OH)2D3 at the indicated 
concentrations alone or in combination with 9cRA. (D) 9cRA-mediated potentiation of cystatin D expression by 
1α,25(OH)2D3 is dose-dependent. (E) tRA synergizes with 1α,25(OH)2D3 to enhance cystatin D expression in a 
dose-dependent fashion. Lysates of SW480-ADH cells treated during 48 h with 1α,25(OH)2D3 and/or 9cRA or tRA 
at the indicated concentrations were analyzed by western blot. Numbers between the blots in (B-E) correspond to 
mean of the fold increase values obtained in two experiments. 
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 Given that the interaction between VDR and RXR in transcription regulation is well known, 
we investigated if any RXR ligands could cooperate with 1α,25(OH)2D3 for cystatin D 
induction. First, we analyzed CST5 promoter induction using 9-cis retinoic acid (9cRA), the 
most recognized RXR ligand, as well as docosahexaenoic acid (DHA), an omega-3 fatty acid 
that has been described as a natural ligand of RXR in mouse brain 55. We transfected the -
650/+262 CST5 promoter fragment in SW480-ADH cells and treated the cells with 
1α,25(OH)2D3 in combination with 9cRA or DHA for 48 h (Figure 19A). CST5 promoter was 
slightly induced by 9cRA (1.8-fold). Importantly, the combination of 9cRA with 1α,25(OH)2D3 
caused a stronger induction of the promoter than that observed with 1α,25(OH)2D3 alone 
(4.6-fold versus 3.2-fold). By contrast, DHA treatment did not activate CST5 promoter alone 
nor synergized with 1α,25(OH)2D3. 
 Next, we examined whether cystatin D protein expression was modified by RAs. SW480-
ADH were treated with different concentrations of 1α,25(OH)2D3 (100 or 0.5 nM) in 
combination with 9cRA (100 nM) or DHA (100 nM) during 48 h and analyzed by western blot. 
Similarly to data obtained in the promoter studies, the induction by 1α,25(OH)2D3 of cystatin 
D protein expression increased following the combined treatment with 9cRA but not with 
DHA (Figure 19B). An extended study using lower concentrations of 1α,25(OH)2D3 
corroborated that 9cRA enhances the induction of cystatin D by 1α,25(OH)2D3 (Figure 19C). 
 We also analyzed if all-trans retinoic acid (tRA), regulates cystatin D expression. tRA binds 
and activates RAR, and has no effect over RXR. Western blot analysis after treatment with 
different concentrations of 1α,25(OH)2D3 and 9cRA, tRA or the combination of 9cRA or tRA 
with 1α,25(OH)2D3 showed that, similarly to 9cRA, tRA increases the induction of cystatin D 
by 1α,25(OH)2D3. Moreover, treatment with different concentrations of 9cRA and tRA  (100, 5 
and 0.5 nM) demonstrated that the effect of both RAs was dose-dependent (Figure 19D and 
19E).   
 These results show that the induction of cystatin D by 1α,25(OH)2D3 is enhanced by both 
RXR and RAR ligands. 
 
4. Ectopic expression of cystatin D in SW480-ADH cells mimics 
partially the effects of 1α ,25(OH)2D3   
 
To examine the contribution of cystatin D to the antitumor action of 1α,25(OH)2D3 we 
expressed ectopically the human cystatin D cDNA in SW480-ADH cells. They were selected 
due to its high response to 1α,25(OH)2D3 treatment, and because these cells are widely used 
as a CRC model since they harbor most of the frequent mutations found in this neoplasia 
(CIN phenotype; wild-type CTNNB1/β-catenin, TGFβRII and BAX, mutated TP53, APC and 
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K-RAS). Expression of exogenous cystatin D protein in transfected clones following antibiotic 
selection was analyzed by western blotting and two clones (#8 and #17) with different 
cystatin D expression levels were selected for further studies. The activity of exogenous 
cystatin D was assessed in enzymatic assays (Figure 20).  
 
 
Figure 20. Ectopic cystatin D expression in stably-transfected SW480-ADH cells. (A) Western blot analysis 
showing the expression of cystatin D protein in G418-selected clones of transfected SW480-ADH cells. (B) Total 
cathepsin activity in selected SW480-CST5 clones. Specific activity was expressed as relative fluorescence units 
(RFU). 
1α,25(OH)2D3 inhibits the proliferation of SW480-ADH cells through the regulation of 
multiple cell cycle-related proteins and the inhibition of β-catenin/TCF4 transcriptional activity 
77,225,303. These findings led us to examine if ectopic cystatin D expression altered the 
proliferation capacity of SW480-ADH cells. For this purpose, CST5-expressing cells were 
treated with 1α,25(OH)2D3 or vehicle.  We observed that exogenous cystatin D decreased 
cell proliferation in a comparable level to that of 1α,25(OH)2D3 and their combination had an 
additive effect (Figure 21). 
 
Figure 21. Ectopic cystatin D expression inhibits proliferation in SW480-ADH cells. SW480-ADH cells 
transfected with empty vector (Mock) or stably expressing CST5 were seeded in 24-well plates and treated for up 
to 6 days with 1α,25(OH)2D3 (100 nM) or vehicle. Living cells were counted after trypsinization. Representative 
data from three independent experiments done in triplicate are shown.  
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Next, we studied if SW480-ADH gene expression was modified by exogenous cystatin D. 
We analyzed several 1α,25(OH)2D3 target genes as CYP24 and CDH1. In both cases 
exogenous cystatin D enhanced the induction by 1α,25(OH)2D3 (1.4- and 2.5-fold increase of 
RNA levels, respectively) (Figure 22A left and middle panels). In case of E-cadherin, this 
increased induction was also observed at the protein level (1.6-fold) (Figure 22B).  
 
 
Figure 22. Ectopic cystatin D expression alters gene expression in SW480-ADH cells. (A) Quantitative RT-
PCR analysis showing the level of CYP24 (left), CDH1 (middle), and LEF1 (right) RNA in cystatin D-expressing 
cells. (B) Western blot analysis showing changes in E-cadherin, c-MYC, and LEF-1 proteins in cystatin D-
expressing cells. (C) Cystatin D inhibits SNAI1 expression. Quantitative RT-PCR (left) and western blot (right) 
analyses showing reduced SNAI1 RNA and protein levels in cystatin D-expressing cells. Numbers between the 
blots in (B and C) correspond to mean of the fold change values obtained in two experiments.  
 
As cystatin D inhibited cell proliferation we analyzed the expression of c-MYC, an 
oncogene that controls several cell proliferation related genes, acting as a key cell cycle 
regulator. Moreover, c-MYC is downregulated by 1α,25(OH)2D3 34,228,229. We observed that 
cystatin D-expressing cells showed a reduced basal level of c-MYC protein expression. 
Furthermore, exogenous cystatin D enhanced the repression of c-MYC by 1α,25(OH)2D3 
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(57% in cystatin D-expressing cells versus 30% in mock cells) (Figure 22B). Notably, 
exogenous cystatin D decreased RNA and protein levels of the EMT inducer SNAIL1 (37.5% 
and 40% respectively) (Figure 22C). We also studied the effect of ectopic cystatin D 
expression on the mesenchymal marker LEF-1 level. We analyzed RNA and protein 
expression but no significant change was observed (Figure 22A, right panel and 22B).  
These data suggest a possible role of cystatin D as a mediator of some 1α,25(OH)2D3 
antitumor actions. 
 
5. CST5 silencing affects the response of SW480-ADH to 
1α ,25(OH)2D3  
To further investigate the effects of cystatin D on the behavior of SW480-ADH cells after 
1α,25(OH)2D3 treatment and elucidate if this protease inhibitor has an important role in the 
hormone activity, we knocked-down cystatin D by transduction of stable lentiviral shRNA. 
Control cells were infected with a nontargeting shRNA. Western blot analysis showed that 
cystatin D levels in CST5 shRNA cells were severely reduced as compared to control 
following 1α,25(OH)2D3 addition (Figure 23A).  
 
Figure 23. CST5 silencing affects SW480-ADH response to 1α,25(OH)2D3. (A) Western blot analysis showing 
decreased level of cystatin D protein in CST5 shRNA cells treated with 1α,25(OH)2D3 (100 nM) or vehicle. 
Numbers between the blots correspond to mean of the fold change values obtained in two experiments. (B) 
Phase-contrast images of control shRNA and CST5 shRNA cells that were treated with 1α,25(OH)2D3 (100 nM) or 
vehicle for 48 h. Scale bar: 20 µm. (C) CST5 knock-down abrogates the inhibition of cell proliferation by 
1α,25(OH)2D3. Control shRNA and CST5 shRNA cells were treated with vehicle or 1α,25(OH)2D3 (100 nM) for the 
indicated times. Proliferation of cells in 1α,25(OH)2D3- versus vehicle-treated cultures is shown.  
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We observed that CST5 shRNA cells responded distinctly to 1α,25(OH)2D3 treatment that 
control shRNA cells. Thus, CST5 shRNA cells showed an attenuated phenotypic change 
compared with control shRNA cells when they were treated with 1α,25(OH)2D3 (Figure 23B). 
In addition, when we analyzed the antiproliferative effect of 1α,25(OH)2D3 in these cells we 
found that it was abrogated by CST5 knock-down (Figure 23C).  
We also studied if CST5 shRNA cells changed the pattern of gene expression. Conversely 
to the effect observed with cystatin D overexpression, in 1α,25(OH)2D3-treated CST5 shRNA 
cells the induction of CYP24 RNA was significantly lower (73%) than that in control shRNA 
cells (Figure 24A, left panel). Similar results were found for CDH1/E-cadherin RNA and 
protein expression (53% and 35% reduction, respectively) (Figure 24A, middle panel and 
24B). The expression of the mesenchymal marker LEF-1 increased in CST5 shRNA cells 
(1.2-fold) and the 1α,25(OH)2D3-mediated reduction of its RNA level was lower in these cells 
as compared to control shRNA cells (29% versus 42%) (Figure 24A, right panel and 24B). 
Moreover and in contrast with the effects of cystatin D overexpression, CST5 knock-down 
increased c-MYC (2-fold) (Figure 24B) and SNAIL1 (1.5-fold) (Figure 24C) protein 
expression.  
 
Figure 24. CST5 knock-down affects gene expression in SW480-ADH cells. (A) Quantitative RT-PCR 
analysis showing decreased CYP24 (left), CDH1 (middle), and LEF1 (right) RNA expression in CST5 shRNA 
cells. (B) Western blot analysis showing changes in E-cadherin, c-MYC, and LEF-1 proteins in CST5 shRNA 
cells. (C) CST5 knock-down increases the expression of SNAI1 RNA (left) and protein (right). Numbers between 
the blots correspond to mean of the fold change values obtained in two experiments. 
RESULTS 
 
62 
Altogether, these results agree with those obtained by means of ectopic cystatin D 
expression, suggesting a role for this protease inhibitor mediating 1α,25(OH)2D3 antitumor 
activity. 
 
 
6. Cystatin D inhibits proliferation, migration, and anchorage-
independent growth of cultured colon cancer cells and their 
tumorigenic potential in vivo 
 
To examine if cystatin D had any effect in other colon cancer cell lines, we expressed 
ectopically the human CST5 cDNA in LS174T, and HCT116 cells that have undetectable or 
low endogenous levels of this protease inhibitor. Expression of the exogenous cystatin D 
protein in transfected clones following antibiotic selection was analyzed by western blotting 
and two (#9 and #11) or four (#9, #17, #20, #28) clones (LS174T or HCT116, respectively) 
with different cystatin D expression levels were selected for further studies (Figure 25A and 
25B). The activity of exogenous cystatin D was assessed in enzymatic assays (Figure 25C 
and 25D). 
 
Figure 25. Ectopic cystatin D expression in stably-transfected HCT116 and LS174T cells. Western blot 
analysis showing the expression of cystatin D protein in G418-selected clones of transfected (A) HCT116 and (B) 
LS174T cells. Total cathepsin activity in selected (C) HCT116-CST5 and (D) LS174T-CST5 clones. Specific 
activity was expressed as relative fluorescence units (RFU). 
  
Based on the results obtained in SW480-ADH cells we studied if exogenous cystatin D 
inhibited the proliferation of HCT116 and LS174T cells. Indeed, cystatin D overexpression 
drastically decreased the proliferation of both HCT116 (∼ 85%) and LS174T (∼ 54%) cell 
lines (Figure 26A and 26B). Conversely, neither recombinant cystatin D protein added to 
cultured medium nor the non-permeable E-64 pan-cathepsin inhibitor altered the proliferation 
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of these two cell lines, suggesting that this effect requires intracellular mechanisms (Figure 
26C and 26D).  
 
Figure 26. Ectopic cystatin D expression inhibits proliferation of colon cancer cells. Cystatin D inhibits cell 
proliferation of (A) HCT116 and (B) LS174T cells. HCT116 or LS174T cells transfected with empty vector (Mock) 
or stably expressing CST5 were seeded in 24-well plates and after 6 days living cells were counted after 
trypsinization. Representative data from three independent experiments done in triplicate are shown. (C) HCT116 
and (D) LS174T cell proliferation is unaffected by human recombinant cystatin D (hrCyst.D) protein or the non-
permeable E-64 pan-cathepsin inhibitor. Eight thousand cells were seeded and incubated for the indicated times 
in growth medium containing hrCyst.D, E-64 or vehicle. 
 
We also studied two in vitro parameters of cell transformation: migration and anchorage-
independent growth. In these experiments we used HCT116 cells since LS174T cells lack 
basal migration capacity. Cystatin D expression significantly (P < 0.001) reduced migration of 
HCT116 cells in Boyden chamber assays (Figure 27A). Likewise, cystatin D inhibited the 
growth of HCT116 cells in semisolid agar (P < 0.001), and the colonies formed by cystatin D-
expressing HCT116 cells had also a smaller size than that of control cells (Figure 27B). 
 Given that exogenous cystatin D inhibits several parameters of malignancy in vitro we 
examined the antitumor effects of cystatin D in vivo. To this end, we injected subcutaneously 
cystatin D-expressing or control HCT116 or LS174T cells in immunodeficient mice. The 
volume of the tumors was measured every two days and the mice were sacrificed at day 23 
and 24 post-injection, respectively (Figure 28). In both cases, the number of tumors 
generated was drastically inhibited by cystatin D expression, as at the end of the experiment  
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Figure 27. Ectopic cystatin D expression inhibits migration and anchorage-independent growth of 
HCT116 cells. (A) Cystatin D inhibits cell migration. HCT116 cells transfected with empty vector (Mock) or stably 
expressing CST5 were seeded in triplicate on Transwell® filters, and 24 h later migratory cells that had attached to 
the lower surface of filters were counted. Representative images and a quantification of data from three 
independent experiments are shown. (B) Cystatin D inhibits anchorage-independent cell growth. Images of foci 
grown in semisolid agar and quantification are shown. Original magnification, x63. 
 
 
Figure 28. Cystatin D inhibits tumor growth in vivo. Immunodeficient mice were injected subcutaneously with 
(A) mock-transfected HCT116 cells or one of the two clones of HCT116 cells transfected with CST5 (clone #9 or 
#20); or (B) mock-transfected LS174T cells or one of the two clones of LS174T cells transfected with CST5 (clone 
#9 or #11). The volumen of the tumors generated was measured during the indicated period. Inset, number of 
mice developing tumors at the end of the evaluating period. 
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100% of mice injected with control HCT116 or LS174T cells had developed tumors whereas 
this decreased to only 19% and 43% of mice injected with cystatin D-expressing HCT116 or 
LS174T cells, respectively. Tumor volume was also significantly decreased (P < 0.001) in 
both cystatin D-expressing cells. 
 These results show that cystatin D has antitumor activity in colon cancer cell lines 
independently of 1α,25(OH)2D3. 
 
7. Cystatin D induces intercellular adhesion proteins and inhibits 
genes promoting epithelial-mesenchymal transition  
 
Cells expressing exogenous cystatin D exhibited, when they were in culture, a strong 
adhesive phenotype (Figure 29, left panels). Therefore, we analyzed the expression of 
adhesion proteins in these cells. Immunofluorescence and confocal microscopy analyses 
showed that cystatin D-expressing HCT116 cells had increased level of the adherens 
junction E-cadherin and p120-catenin and of the tight junction occludin proteins (Figure 29, 
right panels). This result was also confirmed by western blot analysis (Figure 30A).  
 
 
 
Figure 29. Ectopic cystatin D induces intercellular adhesion. Phase-contrast (left) and confocal microscope 
images (right) of control (mock) and cystatin D-expresing HCT116 cells. Expression of E-cadherin, p120-catenin, 
and occludin proteins was analyzed using specific antibodies. Scale bars: 10 µm (left) and 20 µm (right).  
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We selected E-cadherin for a more detailed study of its regulation by cystatin D. First, we 
corroborated that cystatin D-expressing cells contained higher level of CDH1 RNA than 
control cells (Figure 30B). Moreover, when we assayed the activation of a CDH1 promoter 
fragment (-987/+92) we found that it was more activated in cystatin D-expressing cells than 
in control cells (Figure 30C). As E-cadherin and occludin are targets of transcriptional 
inhibition by genes promoting EMT, we studied whether cystatin D could modulate these 
genes. Using quantitative RT-PCR assays we observed that indeed, cystatin D-expressing 
cells expressed lower level of SNAI2, ZEB1 and ZEB2 RNA than mock cells (Figure 31). In 
contrast, only a weak reduction of SNAI1 and no change of TWIST expression were found.   
 
Figure 30. Ectopic cystatin D regulates E-cadherin expression. (A) Western blot analysis showing the 
induction of E-cadherin and other adhesion proteins by cystatin D in HCT116 cells. Numbers between the blots 
correspond to mean of the fold change values obtained in three experiments. (B) Quantitative RT-PCR analysis 
showing increased levels of CDH1 RNA in cystatin D-expressing HCT116 cells. (C) Effect of ectopic cystatin D on 
CDH1 promoter in HCT116 cells. The cells were transfected with a CDH1 promoter fragment, and luciferase 
activity was measured 48 h later. 
 
 
 
 
 
 
 
 
Figure 31. Cystatin D represses genes involved in EMT. Quantitative RT-PCR analysis of the expression of 
the EMT genes SNAI1, SNAI2, TWIST, ZEB1 and ZEB2 in mock and cystatin D-expressing HCT116 cells. 
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Altogether these results show that cystatin D induces an adhesive phenotype in colon 
cancer cells mediated at least in part by the induction of adhesion proteins and the 
downregulation of their repressors. 
 
8. Cystatin D extends the cell cycle and inhibits β-catenin/TCF 
transcriptional activity and the c-MYC oncogene 
 
To explore the mechanism by which cystatin D inhibits cell proliferation we first performed 
flow cytometry analyses. Cells were synchronized using thymidine and L-mimosine, 
increasing thus the proportion of G1-arrested cells. Cystatin D-expressing cells displayed 
slower entry into cell cycle upon syncronization than control cells, as shown by the lower 
proportion of cells in G2/M phase at 4 hours after release of the cell cycle blockade (Figure 
32). This explains their lower proliferation rate.  
 
 
Figure 32. Cystatin D extends the cell cycle. (A) Cystatin D decelerates cell-cycle entry. Mock and cystatin D-
expressing HCT116 cell clones were stimulated with 10% serum to enter into cell cycle following synchronization 
in G1 phase using double block with thymidine and mimosine as described in Methods, and the proportion of cells 
in each phase was estimated by flow citometry. Asynchronously growing cells were used for comparison (black 
profile). Data from a representative experiment of three performed are shown. (B) Graph representing the mean 
percentage of cells present in each phase of the cell cycle 4 h after release of the blockade. 
RESULTS 
 
68 
We also analyzed c-MYC protein expression. Western blot analysis revealed that cystatin 
D-expressing cells had a decreased level of c-MYC protein (Figure 33A). Consistently, two c-
MYC promoter constructs were less active in cystatin D-expressing cells than in control cells 
(Figure 33B). As the aberrant activation of the Wnt/β-catenin pathway that causes the 
induction of c-MYC and other proliferation and invasion genes is a hallmark of colon cancer 
47,267, we examined its activity in cystatin D-expressing cells. Analogously to 1α,25(OH)2D3 
treatment 225,269, exogenous cystatin D inhibited the transcriptional activity of β-catenin/TCF 
complexes, the downstream effector of the Wnt pathway (Figure 33C). This does not result 
from a general inhibitory effect on transcription as the Notch pathway, evaluated by using a 
Notch intracellular domain (NICD) reporter construct, was not affected by cystatin D 
expression (Figure 33D).  
 
Figure 33. Cystatin D inhibits c-MYC expression and β-catenin/TCF transcriptional activity. (A) Western 
blot analysis showing the decrease in c-MYC protein content in cells expressing exogenous cystatin D following 
the release of cell-cycle blockade. Numbers between the blots correspond to mean of the fold change values 
obtained in three independent experiments. (B) The human c-MYC gene promoter is less active in cystatin D-
expressing cells. Mock and two cystatin D-expressing HCT116 cell clones were transfected with either of two 
constructs of the c-MYC promoter, and luciferase activity was measured 48 h later. (C) β-catenin/TCF 
transcriptional activity is reduced in cystatin D-expressing cells. Mock and two cystatin D-expressing HCT116 cell 
clones were transfected with the wild-type TOP-Flash and mutant FOP-Flash reporter plasmids, and the 
TOP/FOP ratio of luciferase activity was measured 48 h later. (D) Notch function was measured by the degree of 
CBF1 binding using the wild-type 4xCBF1wt-Luc compared with background binding to a mutant 4xCBF1mut-Luc. 
The 4xCBF1wt/4xCBF1mut ratio was measured 48 h later. 
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We conclude that the antiproliferative action of cystatin D is at least in part mediated by the 
repression of the c-MYC oncogene, which in turn is probably mediated partially by the 
inhibitory effect on the Wnt/β-catenin pathway. 
 
9. Cystatin D proteins with reduced antiproteolytic activity maintain 
the antiproliferative but not the migration inhibitory effect  
 
To examine whether the antiproteolytic activity of cystatin D is necessary for its newly 
identified effects on cancer cells, we generated by PCR-mediated mutagenesis two mutant 
forms of this protease inhibitor (Figure 34A). One of these cystatin D mutants had a Gly 
replacing Trp at position 108 (CST5 W108G). This Trp has been described as a crucial 
mediator of cystatin C antiproteolytic capacity (W106 in cystatin C), and its mutation 
(W106G) in this cystatin caused a large decrease in target enzyme affinity 107. Since cystatin 
D has great homology with cystatin C, and although it is known that the region where W108 
is located (loop L2) has a lesser contribution in cystatin D affinity than in cystatin C 5, we 
considered that this mutation would be of interest. We also generated a double mutant that 
carried this mutation and in addition a deletion of the first 12 amino acids (CST5 W108G/Δ1-
12). As it has been already reported, a mutant cystatin D that lacks the first 11 aminoacids 
(N-terminal segment) is mostly inactive as an inhibitor 106.  
 
Figure 34. Generation of cystatin D mutant proteins with reduced antiproteolytic activity. (A) Schematic 
representation of the two cystatin D mutant proteins. CST5 W108G harbors a point Trp to Gly mutation at position 
108 (W108G, highlighted by a black square), while CST5 W108G/Δ1-12 harbors the same W108G mutation 
and a deletion of the first twelve N-terminal aminoacids (in red). (B) Total cathepsin activity in COS-7 cells 
transfected with the indicated cystatin D cDNAs or with empty pcDNA3 vector. (C) Western blot analysis showing 
the expression of CST5 W108D and CST5 W108G/Δ1-12 proteins in HCT116 cells. Numbers between the blots 
correspond to mean of the fold change values obtained in three independent experiments.  
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Mutations were verified by sequencing, and the loss of cysteine protease activity was 
checked by transfecting the mutant CST5 constructs in COS-7 cells (Figure 34B). To 
evaluate if mutant cystatin D proteins retained the previously reported antitumor activity, we 
expressed them in HCT116 cells and verified their expression by western blot (Figure 34C). 
 
Figure 35. Mutant cystatin D proteins distinctly affect cell proliferation, migration and gene expression. 
(A) CST5 W108G and CST5 W108G/Δ1-12 have the same antiproliferative effect as wild-type cystatin D. (B) 
Western blot analysis showing E-cadherin, p120-catenin, and c-MYC protein expression in cells expressing 
mutant cystatin D proteins. Numbers between the blots correspond to mean of the fold change values obtained in 
three independent experiments. (C) Quantitative RT-PCR analysis showing the RNA levels of CDH1 in cells 
expressing either wild-type or mutant cystatin D proteins. (D) CST5 W108G and CST5 W108G/Δ1-12 lack 
migration-inhibitory activity. (E) Quantitative RT-PCR analysis showing the RNA levels of SNAI1, ZEB1, and 
ZEB2 in cells expressing either wild-type or mutant cystatin D proteins. 
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 Next, we studied their effects on cell proliferation. Similar to the results obtained with wild-
type cystatin D, both mutant proteins inhibited cell proliferation (Figure 35A). In view of this 
result, we analyzed c-MYC protein expression, and in line with their antiproliferative effect we 
observed that mutant proteins decreased the level of this protein, similarly to wild-type 
cystatin D (Figure 35B).  
 However, when we analyzed other parameters affected by wild-type cystatin D 
expression, as the migration capacity of the cells, we observed that in contrast to the 
previous findings with wild-type protein, none of the two mutant cystatin D decreased cell 
migration (Figure 35D). In addition, cells expressing either of the mutant cystatin D proteins 
did not show an adhesive phenotype like wild-type cystatin D-expressing cells. Therefore, we 
studied the effect of both cystatin D mutants on adhesion proteins. As it can be seen in 
Figure 35B, and also in contrast to wild-type cystatin D, the two mutant proteins decreased 
E-cadherin, while they did not alter p120-catenin expression. The decreased expression of 
E-cadherin was also studied at the RNA level, with similar results as that observed at the 
protein level (Figure 35C). Consistently, when we studied the expression of EMT genes 
(Figure 35E), the two mutant cystatin D proteins failed to inhibit ZEB1 RNA expression and 
were less efficient than wild-type cystatin D to repress ZEB2. Moreover, they slightly 
increased the expression of SNAI1 RNA.  
Altogether, these results indicate that the inhibition of cysteine proteases is only partially 
responsible for the effects of cystatin D in colon cancer cells. 
 
10. Cystatin D expression decreases in human colorectal 
tumorigenesis in good correlation with tumor dedifferentiation and 
the loss of VDR and E-cadherin expression 
 
Previous results show the effects of cystatin D in colon cancer cell lines. We wished to 
analyze the relevance of our results on human colon cancer. To this purpose, we first studied 
the expression of cystatin D protein in tissue microarrays containing tumor and adjacent 
normal tissue samples. This study was performed in collaboration with Dr. Aurora Astudillo’s 
group from Servicio de Anatomía Patológica, IUOPA-HUCA, Oviedo.   
By inmunohistochemical analysis we studied samples with diverse differentiation grade: 
non-tumor tissue (n = 7), well-differentiated (n = 7), moderately-differentiated (n = 24) and 
poorly-differentiated  (n = 13) tumors.  We found a progressive loss of cystatin D expression 
that correlated with tumor dedifferentiation: while in normal tissue, polyps, and well-
differentiated carcinomas cystatin D showed a strong staining, its expression decreased 
significantly in moderately-differentiated carcinomas (12.5% showed negative staining and 
no samples presented a very high level of staining) and was absent in a high proportion of 
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poorly-differentiated tumors (38.5%, and no samples had high or very high staining level). In 
line with previous studies 236 a correlation between downregulation of VDR and poor 
differentiation of colorectal tumors was found (Figure 36).  
 
 
Figure 36. Cystatin D expression is downregulated during human colon cancer progression. (A) 
Immunohistochemical analysis of cystatin D and VDR expression in tissue microarrays. Counterstaining was with 
hematoxylin. Representative slices of non-tumor tissue and of well-, moderately-, and poorly- differentiated 
carcinomas. Scale bar: 200 µm. (B) Quantification of cystatin D expression by estimation of staining intensity as 
described in Methods. The number of samples analyzed per group and the percentage corresponding to each 
level of cystatin D staining are shown. 
 
These results were confirmed by western blot analysis. We analyzed cystatin D expression 
in colonic normal and tumor tissue samples from 32 CRC patients. We also analyzed the 
expression of VDR and E-cadherin due to their known role as markers of differentiation of 
human colorectal tumors 236. Results are expressed as tumor versus normal (T/N) ratio of 
normalized protein levels of cystatin D, VDR and E-cadherin. We defined overexpression and 
reduction as changes of at least 2-fold in protein level. In 40% (13/32) cases, the level of 
cystatin D was lower in tumor than in normal tissue, in 44% (14/32) was equal in tumor and 
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normal tissue and only in 15% (5/32) the level of cystatin D was greater in tumor than in 
normal tissue (Figure 37).  
 
Figure 37. Cystatin D expression in colon carcinomas. (A) Representative western blot showing the 
expression of cystatin D, VDR, and E-cadherin proteins in a series of matched normal (N) and tumor (T) human 
colon tissues. (B) Percentage of patients in each group of normalized cystatin D protein expression. CRC patients 
were classified in three subgroups: less expression in tumor than in normal tissue (T/N ≤ 0.5), equal expression in 
tumor and normal tissue (0.5 < T/N < 2.0) or more expression in tumor than in normal tissue (T/N ≥ 2.0). 
 
Additionally, we represented the results in two scattergrams (Figure 38A) where one axis 
corresponds with the expression [as log2 (T/N)] of VDR or E-cadherin, and the other one with 
that of cystatin D. We found a strong direct correlation between the expression of cystatin D 
and VDR (Spearman correlation coefficient r = 0.562; P = 0.001) supporting that the 
regulation of cystatin D expression by 1α,25(OH)2D3 observed in cultured cells and 
xenografts may also take place in human colon cancer. Moreover, the expression of cystatin 
D also correlated with that of the E-cadherin (Spearman correlation coefficient r = 0.492; P = 
0.005).  
Subsequently, we analyzed the data considering cystatin D expression as a qualitative 
variable and we divided the patients in two groups according with high (50% of samples) or 
low (50% of samples) cystatin D expression.  Box-plot analysis of VDR and E-cadherin 
expression regarding to that of cystatin D revealed that both VDR and E-cadherin expression 
was significantly greater in tumors with high cystatin D expression than that with low one 
(Kruskal-Wallis test P = 0.001 and P = 0.006, respectively) (Figure 38B). 
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From these results we conclude that cystatin D expression directly correlates with that of 
VDR and E-cadherin in colon carcinomas both associated with tumor dedifferentiation. 
 
Figure 38. Cystatin D expression directly correlates with that of VDR and E-cadherin in colon carcinomas. 
(A) Scattergram showing the relationship between the log2 tumor versus normal (T/N) ratio of normalized protein 
levels of cystatin D and VDR (left) or E-cadherin (right). (B) Box-plot of the log2 T/N ratio of normalized VDR (left) 
or E-cadherin (right) expression in samples with high or low cystatin D levels in the colorectal cancer series. 
Boxes include values in the 25%-75% interval; internal lines represent the median; the outliers (circles) of the 
VDR and E-cadherin expression are indicated.  
11. Gene expression profile induced by cystatin D  
In view of the newly identified effects of cystatin D in colon cancer cells, and considering the 
evidence of cathepsin inhibition-independent mechanisms involved in them, we analyzed 
using oligonucleotide microarrays changes in gene expression related with cystatin D 
overexpression in HCT116 cells (MIN phenotype; wid-type TP53 and APC, mutated K-RAS, 
CTNNB1/β-catenin, PI3KCA and TGFβRII). For these assays we used two different clones of 
cells expressing exogenous cystatin D (#9 and #20) as well as mock and wild-type cells. The 
two clones were used as biological replicates (HCT116 CST5), and the same criterion was 
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assumed to mock and wild-type cells (HCT116 Control). We considered cystatin D-regulated 
genes those with at least 1.5-fold difference in expression as compared to Control cells. This 
analysis revealed that cystatin D overexpression modifies the expression of 69 genes: 23 
genes were upregulated (33%) whereas 46 genes were downregulated (67%). 
 These genes were classified according to their function. Figure 39 shows the most 
represented categories and the percentage of genes in each one. The categories with a 
greater number of genes were cell adhesion, cytoskeleton and extracellular matrix, followed 
by transcription and signal transduction.  
 
 
 
Figure 39. Functional distribution of candidate target genes regulated by cystatin D overexpression in 
HCT116 cells. The most represented categories and the percentage of genes included in each one are shown.  
 
 
Table VII shows the genes included in each category. We found genes such as CDH1 or 
CTNND1 whose regulation by exogenous cystatin D was already showed in this work. 
However, CTNND1, which encodes p120-catenin, is not present in the table since its value 
(1.19) does not achieve the criterion used in the analysis. 
 Exogenous cystatin D increased the expression of important genes related with cell 
adhesion such as CDH1 or CLDN7, which encode proteins of adherens and tight junctions, 
respectively, or JUP (1.46) that encodes desmoplakin-3, a desmosomal protein. In addition, 
exogenous cystatin D inhibited the expression of other cell adhesion and cytoskeleton 
related genes such as VCAN, MSN or VIM, which have been related with cancer progression 
43,152,257,271,329.  
 Several transcription factors such as MEF2C, SOX4, RUNX2 or ID3 were induced, 
whereas NPAS2, RUNX1 or ELK3 were inhibited by exogenous cystatin D. Notably, all 
genes related with metabolism regulated by cystatin D in microarray data were inhibited. 
 We validated various genes regulated by cystatin D in the microarray study analyzing by 
quantitative RT-PCR their expression in cystatin D-expressing HCT116 clones #9 and #20. 
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This study confirmed the regulation of 12/13 genes (considering regulation a 2-ΔΔCT ≥ 2.00 for 
induced genes and 2-ΔΔCT ≤ 0.50 for inhibited ones, calculated as described in Materials and 
Methods). As control we used two endogenous genes (18S and GADPH) and similar results 
were observed (Figure 40). 
  
Table VII. Genes regulated by cystatin D overexpression in HCT116 cells 
Gene Symbol Title   RNA level 
TRANSCRIPTION 
MEF2C Myocyte-specific enhancer factor 2C 4.26 
AP1M2 Adaptor-related protein complex mu-2 subunit 3.77 
SOX4 Transcription factor SOX (SRY-related HMG-box) 4 2.40 
RUNX2 Runt-related transcription factor 2 2.17 
ID3 Inhibitor of DNA binding 3 2.14 
JARID1B Histone demethylase Jumonji/ARID domain-containing protein 1B 1.73 
ELK3 ETS domain-containing protein Elk-3 0.65 
RUNX1 Runt-related transcription factor 1 0.58 
NPAS2 Neuronal PAS domain-containing protein 2 0.51 
TESC Tescalcin 0.47 
   
CELL ADHESION, CYTOSKELETON AND EXTRACELLULAR MATRIX 
CDH1 E-cadherin 3.63 
KRT23 Keratin type I cytoskeletal 23 2.00 
CLDN7 Claudin 7 1.91 
IGSF9 Immunoglobulin superfamily member 9 1.80 
MYO10 Myosin X 1.55 
LAMC1 Laminin subunit gamma-1 precursor 0.65 
STEAP1 Metalloreductase STEAP1 (six-transmembrane epithelial antigen of 
prostate 1) 
0.61 
MSN Moesin 0.58 
EMP3 Epithelial membrane protein 3 0.56 
TSPAN5 Tetraspanin 5 0.54 
COL12A1 Collagen alpha-1 (XII) chain precursor 0.53 
FRAS1 Extracelullar matrix protein FRAS1 precursor 0.53 
VIM Vimentin 0.42 
CEP170 Centrosomal protein of 170 kDa 0.35 
VCAN Versican core protein precursor 0.25 
   
METABOLISM 
TXN Thioredoxin 0.66 
AKR1C2 Aldo-keto reductase family 1 member C2 0.65 
DDT D-dopachrome decarboxylase 0.64 
NT5DC3 5’-nucleotidase domain containing 3 isoform 1 0.60 
CYBRD1 Cytochrome b reductase 1 0.59 
PYGB Glycogen phosphorylase brain form 0.58 
GDA Guanine deaminase 0.57 
GALNT5 Polypeptide N-acetylgalactosaminyltransferase 5 0.47 
NT5E 5’-nucleotidase precursor (CD73 antigen) 0.20 
   
SIGNAL TRANSDUCTION 
SYT7 Synaptotagmin 7 1.53 
GRAP1 GRB2-related adapter protein 1.51 
ARHGAP12 Rho-GTPase-activating protein 12 0.59 
PDCL3 Phosducin-like protein 3 0.57 
AKAP12 A-kinase anchor protein 12 0.57 
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 0.52 
ARHGAP29 PTPL1-associated RhoGAP 1 0.42 
ANXA3 Annexin A3 0.40 
VSNL1 Visinin-like protein 1 0.23 
NAV3 Neuron navigator 3 0.17 
   
 Table follows on the next page  
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Gene Symbol Title RNA level 
CHANNELS AND TRANSPORTER 
SLC1A3 Excitatory amino acid transporter 1 2.51 
ATP8B1 Probable phospholipid-transporting ATPase 1C 2.43 
ATP2C2 Calcium-transporting ATPase type 2C member 2 1.77 
TMC4 Transmembrane channel-like protein 4 1.59 
RBP1 Cellular retinol-binding protein 0.62 
SLC7A11 Cystine/glutamate transporter 0.60 
   
ENDOCYTOSIS 
MAL2 MAL 2 8.03 
EPN3 Epsin 3 1.58 
VTI1B Vesicle transport v-SNARE protein Vti-1 like 1 0.65 
SNX30 Sortin nexin 30 0.62 
   
RECEPTORS AND LIGANDS 
NR3C1 Glucocorticoid receptor 0.55 
NRP1 Neuropilin 1 precursor 0.53 
WNT16 Protein Wnt 16 precursor 0.36 
   
RNA SPLICING 
RBM47 RNA-binding protein 47 1.77 
RBM35A RNA-binding protein 35A 1.62 
RNPC3 RNA-binding region containing 3 0.56 
   
CELL GROWTH AND APOPTOSIS 
PPP2R5A Serine/threonine-protein phosphatase 2A 56kDa regulatory subunit 
alpha isoform 
0.63 
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 0.51 
   
OTHERS 
KIA1199 KIA1199 1.79 
PRSS8 Prostasis precursor 1.75 
OBFC1 Oligonucleotide/oligosaccharide-binding fold containing protein 1 0.65 
OTUD4 OUT-domain containing protein 4 0.65 
FAM133B FAM133B 0.64 
SH3TC2 SH3 domain and tetratricopeptidase repeats-containing protein 2 0.58 
C21orf63 Uncharacterized protein C21orf63 precursor 0.57 
 
Data obtained in microarrays can be considered consistent because: (a) the experimental 
design includes two different cystatin D-expressing clones considered as replicates, as well 
as mock and wild-type cells as duplicated, a criterion that excluded genes regulated in only 
one sample; (b) the criteria used to consider genes as regulated were strict enough to 
eliminate some previously validated genes such as CTNND1; and (c) the high percentage of 
genes validated by quantitative RT-PCR  (92%). 
  Data from microarrays and quantitative RT-PCR show that cystatin D overexpression in 
HCT116 cells regulates genes involved in diverse cellular functions. We are aware that these 
are preliminary data and that a second validation using independent sets of RNA is needed. 
Moreover, validation of these target genes in other cell types as well as functional studies are 
required to support these results.  
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Figure 40. Validation of selected cystatin D-regulated genes in HCT116 cells. Quantitative RT-PCR analysis 
showing the RNA levels of upregulated (A and B) and downregulated (C and D) genes. In each case the genes 
were normalized both to 18S (A and C) and GAPDH (B and D). Normalized mean values and SD obtained in two 
independent experiments are shown. 
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CRC is one of the most important neoplasias worldwide in terms of prevalence and mortality. 
The accepted idea that CRC takes many years to develop enables prevention and early 
detection. Surgery remains the primary treatment while chemotherapy and/or radiotherapy 
are recommended depending on the individual patient staging but are rarely curative 
76,79,138,191. 1α,25(OH)2D3 is the most active metabolite of vitamin D3 in human body and has 
numerous antitumor actions 56. Previous data from our laboratory and others have shown 
that 1α,25(OH)2D3 regulates the proliferation and phenotype of colon carcinoma cells through 
the transcriptional control of a number of target genes and the antagonism of the Wnt/β-
catenin signaling pathway 225,227. These results contribute to explain the higher susceptibility 
to colon cancer caused by vitamin D deficiency in animal models and the results of 
epidemiological and clinical studies that sustain a protective and perhaps therapeutic role of 
1α,25(OH)2D3 against CRC 85,96,167,205.  
Cystatin D is a secreted protease inhibitor found in human saliva and tear fluid 83.  It was 
first identified as the product of a gene with homology to the cystatin C gene and its 
sequence contains all regions of relevance for cysteine proteinase inhibitory activity and also 
the 4 cysteine residues that form disulfide bridges in the other members of Type 2 cystatins 
82. However, the inhibition profile of cystatin D is clearly different from that of other members 
of its family. Cystatin D is unable to inhibit cathepsin B and pig legumain, displaying a more 
restricted and specific inhibition profile than its homologues 5. Probably, due to its unusual 
expression and inhibition profiles, cystatin D has an unknown biology that has allowed to 
discover new functions for this protease inhibitor. 
Our work has revealed new and unexpected actions of cystatin D that propose it as a 
candidate tumor suppressor gene in colon cancer. Moreover, in this Thesis we report that 
1α,25(OH)2D3 is a strong direct inducer of cystatin D in human colon cancer cells, and that 
this cathepsin proteases inhibitor partly mediates 1α,25(OH)2D3 antitumor activity. 
 
1. Cystatin D and its new identified tumor suppressor activity 
 
Many proteases, particularly those that degrade ECM, play an important role in tumor 
development providing an access for tumor cells to the vascular and lymphatic systems, thus 
favoring angiogenesis and invasion. Moreover, certain proteases also promote tumor cell 
proliferation and resistance to apoptosis showing that proteolytic enzymes can contribute to 
all stages of tumor progression 33,63,195. This is the case of lysosomal cysteine proteases, 
which have been implicated in multiple steps during tumor progression including early steps 
of immortalization and transformation, intermediate steps of tumor invasion and 
angiogenesis, and late steps of metastasis and drug resistance 140. Thus, cathepsins B and S 
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seem to contribute to the angiogenic switching and basement membrane degradation in the 
early preneoplastic lesions. Likewise, cathepsins B, C, L, and Z potentiate the release and 
activation of pro-growth factors thus favouring tumor growth. On the other hand, cathepsins 
H and L contribute to invasive growth either through degradation of basement membrane or 
ECM components or proteolysis of specific target proteins on the cell-surface 91,92,140,161. All 
these pro-tumorigenic properties of cathepsins are balanced by the activity of different 
members of the cystatin family. Thus, cystatin E/M, is a known tumor suppressor gene in 
human breast cancer that is normally downregulated and epigenetically silenced in this 
neoplasia 150,270,333. Moreover, cystatin C has been proposed as a TGFβ receptor antagonist 
275,276. The data reported in this Thesis sustain a similar and, unpredicted role of cystatin D as 
a candidate tumor suppressor gene.  
 
1.1 Cystatin D inhibits several transformation parameters of human colon 
cancer cells  
Stimulation of cell proliferation, morphological alteration, migration capacity or anchorage 
independence are transformation parameters that collaborate in tumor progression as well as 
in metastatic processes. Our results demonstrate that exogenous cystatin D promotes the 
inhibition of the proliferation, migration and anchorage-independent growth of cultured colon 
cancer cells and their tumorigenic potential in vivo.   
We observed that exogenous cystatin D inhibits cell proliferation in all three colon cancer 
cell lines studied. The finding that addition of recombinant cystatin D protein to cells did not 
reproduce the effects of endogenous cystatin D indicates that its antitumor effects are mostly 
exerted intracellularly. Flow cytometry assays showed a slower entry of cystatin D-
expressing cells into cell cycle upon synchronization as compared to cystatin D negative 
cells. This antiproliferative action of cystatin D in vitro as well as the antitumor growth in vivo 
on colon cancer cells is most probably linked to the repression of c-MYC oncogene. Cystatin 
D decreased c-MYC RNA and protein levels and also the activation of two different c-MYC 
promoter constructs, suggesting a transcriptional regulation. We also observed the inhibition 
of β-catenin/TCF transcriptional activity. This interference with the Wnt signaling pathway can 
explain at least partially the downregulation of c-MYC since this oncogene is a known target 
of Wnt/β-catenin pathway 114. Remarkably, the suppression of c-MYC overexpression is 
sufficient to cause sustained tumor regression in several model systems, and a threshold 
level of c-MYC protein is required for tumor maintenance (268 and references therein). 
Indeed, c-MYC has a crucial role in cell proliferation. It is known that c-MYC abrogates the 
transcription of cell cycle checkpoint genes (for example, GADD45 and GADD153), inhibits 
the function of cyclin-dependent kinase (CDK) inhibitors (reviewed in 46), and promotes cell 
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cycle progression by activation of several cyclins (cyclin E1, cyclin A2…), as well as CDK4, 
E2F1, E2F2 and other proteins 137,172,235. In addition, and although its regulation by cystatin D 
seems to be modest, cyclin A2 is one of the genes downregulated by cystatin D 
overexpression in our global transcriptomic analysis.  
Migration and anchorage-independent growth were also inhibited by cystatin D in colon 
cancer cells. These are characteristics of transformed cells. Moreover, they are involved in 
the metastatic process allowing the cells to leave the original tumor site and reach other 
parts of the body. Cathepsins have been related several times with these processes and thus 
cathepsin B, L, X, C or S participate in tumor formation, growth, migration and invasion 158-
160,196,312. Cystatins have been reported as inhibitors of these processes, and thus, cystatin C 
and E/M diminish migration and anchorage-independent growth in various cancer cell types 
270,275,276,333. Since cystatin D inhibits some of these proteases, our results are coherent and 
agree with these findings. 
 
1.2 Role of cystatin D regulating adhesion proteins and their inhibitors   
One of the most notable effects of ectopic cystatin D expression is the induction of an 
adhesive phenotype (HCT116 cells). Molecular analyses showed the induction by cystatin D 
of adhesion proteins such as E-cadherin, p120-catenin or occludin. These are central 
proteins for the formation of adherens and tight junctions. They are essential for cell-cell 
interaction in epithelial tissues and their disruption abrogates normal embryonic development 
and is a common occurrence in metastatic cancers 9,50,59,89,188,210.  
Cadherins are of particular importance for the dynamic regulation of adhesive contacts. In 
adult tissue they are involved in the orderly turnover of rapidly growing tissues such as the 
lining of the gut and the epidermis 116,293. Cadherins are also responsible for the maintenance 
of stable tissue organization to prevent the dissociation and spread of tumor cells 27,39. Thus, 
in epithelial derived tumors, loss of cell-cell adhesion is correlated with downregulation of E-
cadherin as well as increased proliferation and tumor invasiveness 49,51. E-cadherin is the key 
molecule of the cadherin-catenin-cytoskeleton complex, and it is important for establishing 
and maintaining apico-basal polarity, preserving epithelial cell survival, and controlling 
proliferation 175. Perturbation of E-cadherin/catenin complex leads to a dissociation of β-
catenin that accumulates in the cytoplasm, translocates to the nucleus and interacts with 
TCF/LEF transcription factors altering the expression of genes involved in cell proliferation, a 
signaling pathway activated by Wnt factors 203. Moreover, disassembly of adherens junctions 
causes loss of E-cadherin mediated adhesion and promotion of cell migration 151,185.  
p120-catenin has a crucial role stabilizing the cadherin/catenin complex and it is known 
that p120-catenin/E-cadherin interaction is required for increased adhesiveness of cells 292. 
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Due to this role it is not surprising that many cancer types are characterized by loss or 
dislocalization of p120-catenin (reviewed in 306). Occludin has also been related with cancer 
progression and thus, by the regulation of RhoA signaling this adhesion protein participates 
in cell cycle progression 3,25,327. 
The increased expression of these adhesion proteins by cystatin D was associated with 
the downregulation of EMT genes. EMT is a process whereby epithelial cell layers lose 
polarity and cell-cell contacts and undergo a dramatic remodeling of the cytoskeleton 291. A 
hallmark of EMT is the loss of E-cadherin expression. Loss of E-cadherin is consistently 
observed at sites of EMT during development and cancer 291. Several developmentally 
important genes that induce EMT have been shown to act as E-cadherin repressors. And 
thus, SNAIL1, SNAIL2, ZEB1, ZEB2, TWIST or E47 bind to the E-boxes at the CDH1 
promoter and repress E-cadherin expression 48,190,208. These genes also downregulate 
occludin expression 127. Therefore, disruption of intercellular junctions causes dissociation of 
epithelial cells from surrounding cells, acquiring mesenchymal-like characteristics and 
becoming able to migrate away from the original tissue.  
In conclusion, the downregulation of EMT genes linked to enhanced expression of E-
cadherin and other adhesive proteins, as well as the inhibition of cell migration and 
proliferation observed in cystatin D-expressing cells, imply the reversion of the transformed 
phenotype, hallmark of the EMT process, and the acquisition of epithelial and less 
aggressive characteristics.  
  
1.3 Are all the antitumor effects of cystatin D mediated by its cathepsin-
inhibitory activity? 
In this Thesis we show novel and complex actions of cystatin D on colon cancer cells, but 
the exact molecular mechanism by which cystatin D exerts its actions is unclear. The more 
reasonable possibility is based on its antiproteolytic activity. However, our results derived 
from the functional analysis of mutant cystatin D proteins with reduced antiproteolytic activity 
indicate that cystatin D exerts its antimigratory effects as well as the regulation of adhesion 
proteins and their inhibitors through cathepsin inhibition, while its antiproliferative effect on 
colon cancer cells seems to be independent of this activity (Figure 41). 
It is known that one of the mechanisms to downregulate E-cadherin expression is based 
on the proteolytic cleavage of its ectodomain by proteases such as MMP-3 and -7 or 
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ADAM10, among others 185,211.  In line with this, the cystatin D targets cathepsin L and S 
have been reported to cleave E-cadherin in vitro and possibly in Rip1-Tag2 (RT2) mice∗ 92. 
 
 
 
 
 
Figure 41. Schemes showing the interplay between E-cadherin, EMT genes, cathepsins and β-catenin in 
the control of cell adhesion, proliferation and migration. (A) Normal epithelial cell. (B) Carcinoma cell. (C) 
Blockade of colon carcinoma cell migration by cystatin D via cathepsin inhibition-dependent mechanisms. (D) 
Blockade of colon carcinoma cell proliferation by cathepsin inhibition-independent mechanisms. Grayed out 
represent the processes inactive in each situation. Processes inhibited are highlighted in red and those induced 
are highlighted in black.  
                                                        
∗ RIP-Tag mice carry the SV40 early region encoding the large T (Tag) and small t oncoproteins under the control 
of the rat insulin gene regulatory region (RIP). Tag abrogates the functions of the retinoblastoma and p53 tumor 
suppressors in the pancreatic islet β cells, leading to the formation of β cell tumors (insulinomas) in every mouse 
inheriting the hybrid oncogene. 
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RT2 transgenic mice, that are models of multistage cancer, develop multiple pancreatic 
islet tumors, and E-cadherin downregulation has been functionally implicated in acquisition of 
the invasive growth phenotype in this pathway 238.  Thus, cathepsin L and S knockout 
(CtsL−/− RT2, and CtsS−/− RT2) mice maintained E-cadherin protein levels in comparison with 
control RT2 mice and this is associated with a pronounced reduction in tumor invasion in vivo 
92 In addition, a shorter isoform of cathepsin L lacking the signal peptide is present within the 
nucleus of mouse 3T3 and human breast cancer cells and modulates the proteolytic 
processing of the CCAAT-displacement protein/cut homeobox (CDP/Cux) transcription factor 
generating a p110 isoform 97. The p110 CDP/Cux isoform has been related with the 
regulation of cell cycle progression 264. Moreover, it has recently been showed that p110 
CDP/Cux binds to and activates the SNAI1 and SNAI2 gene promoters, cooperating with 
these transcription factors in the repression of E-cadherin, thereby causing disorganization of 
cell-cell junctions 146. 
 In human colon cancer cells, however, we did not detect the E-cadherin cleaved fragments 
(64 and 30-35 kDa) that are generated by cathepsin L. Likewise, we found no changes in the 
expression of CDP/Cux polypeptides associated with cystatin D expression (data not shown). 
These differences may be due to species- and/or cell type- specific activity of cathepsin L. 
Due to the opposite regulation of CDH1 RNA levels observed between wild-type and mutant 
cystatin D protein-expressing cells, as well as in that of EMT genes, it is reasonable that 
another still uncharacterized cathepsin-mediated mechanism is taking place in our system. 
Alternatively, the recent description by Weinberg’s group 184,219 that E-cadherin loss in breast 
cancer cells promotes cancer stem cell–like properties and metastasis through the induction 
of EMT suggests that cystatin D may primarily affect CDH1 RNA transcription or stability.  
In addition, cystatin D has effects unrelated to the inhibition of cathepsins such us 
proliferation arrest or the downregulation of c-MYC expression. Cystatin D may exert these 
actions by interacting with other non-characterized proteins. In recent years, cystatins have 
been proposed to play important roles in tumor progression apparently unrelated to their 
cathepsin-inhibitory action, and numerous studies involving cystatins C and E/M have 
described this dual function 270,276. Thus, cystatin E/M, similarly to cystatin D, exerts its 
antiproliferative effect in breast cancer cells independently of cathepsin inhibition 270. 
Likewise, cystatin C, via a cathepsin-independent mechanism, antagonizes TGFβ signaling 
pathway by interacting physically with the TGFβ type II receptor and antagonizing the binding 
of TGFβ 276. Moreover, another illustrative example in this regard is that of the tissue inhibitor 
of metalloproteinases (TIMP)-2, which inhibits mitogenesis and angiogenesis at least in part 
by metalloproteinase-independent mechanisms 282.  
The finding that mutant cystatin D proteins with reduced antiproteolytic activity inhibit cell 
proliferation but not cell migration makes plausible that both, cathepsin inhibition-dependent 
DISCUSSION 
 
87 
and -independent mechanisms are responsible for cystatin D antitumor activity. This novel 
dual action suggests future studies aimed to identify new mechanisms or cystatin D-
interacting proteins.  
2. Cystatin D is an important mediator of 1α ,25(OH)2D3 action in 
colon cancer  
Numerous studies have shown that 1α,25(OH)2D3 is a major transcriptional regulator of gene 
expression. Identification of novel 1α,25(OH)2D3 target genes is necessary to understand the 
anti-cancer role of this hormone. An important finding of this Thesis has been to identify and 
characterize the direct regulation of cystatin D expression by 1α,25(OH)2D3 and describe the 
role of this inhibitor as mediator of 1α,25(OH)2D3 actions against colon cancer.  
 
2.1 1α,25(OH)2D3 induces cystatin D expression in colon cancer cell lines 
Our results demonstrate that 1α,25(OH)2D3 increases CST5 RNA and protein expression in 
human colon cancer cells. They validate previous results of our laboratory using 
oligonucleotide microarrays that showed an increase in the level of CST5 RNA following 
1α,25(OH)2D3 treatment of SW480-ADH cells 227. Previously, cystatin E/M was identified as a 
target of the 1α,25(OH)2D3 analog EB1089 in squamous carcinoma cells. The upregulation of 
cystatin E/M by the hormone was confirmed by Northern blot and immunofluorescence 
analyses, but no functional studies has been reported yet 176. In addition, cystatin A is 
induced by 1α,25(OH)2D3 in normal keratinocytes. This regulation is mediated by inhibition of 
Raf-1/MEK1/ERK signaling pathway via a non-genomic response 287. Moreover, 
1α,25(OH)2D3 also regulates the expression of other protease inhibitors such as TIMPs or 
plasminogen activators inhibitors (PAIs). Thus, TIMP-1 is upregulated by 1α,25(OH)2D3 in 
breast and prostate cancer cells as well as PAI-1 in breast cancer cells 14,154.  
The finding that the increase of cystatin D by 1α,25(OH)2D3 was abrogated by the 
transcription inhibitor actinomycin D but not by the translation inhibitor cycloheximide 
indicated a direct transcriptional effect of 1α,25(OH)2D3. Moreover, transactivation and ChIP 
assays showed that this activation is mediated by the binding of VDR to a cluster of sites 
located close to the transcription start site at the cystatin D promoter. These studies also 
showed that a functional VDR was needed for this activation. Recently, it has been proposed 
that isolated, simple VDREs may be not functional in vivo, and that, contrarily, transcription 
factor binding site clusters or modules contribute to chromatin decondensation allowing a 
major accessibility of transcription factors to a promoter 41. Our results fit with this theory and 
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can explain why the region of CST5 promoter with a greater number of VDREs is most 
activated by 1α,25(OH)2D3 with lower or no contribution of isolated VDREs.  
We have also shown that 1α,25(OH)2D3 regulates cystatin D expression in other colon 
cancer cell lines, which supports a general regulation of this inhibitor by 1α,25(OH)2D3 in 
colon cancer. In addition, the finding that cystatin D was also regulated by EB1089 in 
xenografted mice sustains a role for 1α,25(OH)2D3 in the regulation of cystatin D in vivo. 
 
2.2 Cystatin D mimics the effect of 1α,25(OH)2D3 treatment 
The number and importance of the actions of cystatin D and its strong, rapid and direct 
transcriptional regulation by 1α,25(OH)2D3 indicate that cystatin D is an important mediator of  
1α,25(OH)2D3 action in colon cancer cells at least in vitro. This is further emphasized by the 
results obtained after expressing an exogenous cystatin D or by down-regulating the 
endogenous CST5 gene by means of shRNA in SW480-ADH cells. In these cells ectopic 
cystatin D expression inhibited cell proliferation at similar levels than that observed only with 
the hormone and, in addition, 1α,25(OH)2D3 treatment enhanced this inhibition. It is known 
that one antitumor actions of 1α,25(OH)2D3 is the inhibition of cell proliferation, and this effect 
is mediated in part by the inhibition of c-MYC expression 34,228,229. c-MYC protein levels 
decreased upon expression of exogenous cystatin D similarly to what happens in cells 
treated with 1α,25(OH)2D3. Additionally, 1α,25(OH)2D3 enhances the inhibition of c-MYC 
caused by cystatin D. These results correlate with the effects observed on cell proliferation, 
explaining the additive effect of 1α,25(OH)2D3 and cystatin D in these cells. 1α,25(OH)2D3 
also regulates other genes involved in cell cycle progression such as p21WAF1/CIP1, p27KIP1, c-
JUN and others (reviewed in 95), which can explain why the treatment of cystatin D-
expressing cells with 1α,25(OH)2D3 lead to a greater inhibition of cell proliferation. The finding 
that cystatin D knockdown completely abrogates the 1α,25(OH)2D3-mediated inhibition of cell 
proliferation suggests that cystatin D is required to the antiproliferative effect of 
1α,25(OH)2D3.  
All effects analyzed in cystatin D-expressing SW480-ADH cells after treatment with 
1α,25(OH)2D3 were inversely regulated by CST5 shRNA. In this way, cystatin D 
overexpression increased the induction of E-cadherin by 1α,25(OH)2D3 while the opposite 
effect was observed in CST5 shRNA cells. Moreover, CST5 knockdown abrogates in part the 
phenotypic change induced by 1α,25(OH)2D3, an effect that may be explained by the 
reduction of E-cadherin-mediated intercellular adhesion. 
Altogether these data suggest a critical contribution of cystatin D mediating the antitumor 
actions of 1α,25(OH)2D3. 1α,25(OH)2D3 promotes apoptosis and induces cell differentiation, 
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and inhibits migration and invasion as a result of the regulation of a high number of target 
genes,. Among them, cystatin D contributes by cathepsin-dependent and independent 
mechanisms to several of these  anticancer activities (Figure 42). 
 
 
 
Figure 42. Scheme showing the role of cystatin D as mediator of 1α,25(OH)2D3 antitumor activity. Among 
the genes regulated by 1α,25(OH)2D3 cystatin D play important roles mediating the hormone antitumor actions 
through cathepsin-dependent and cathepsin-independent mechanisms. 
 
 
3. Cystatin D expression in human colon cancer  
 
Results obtained in this Thesis using human patients’ samples strongly indicate that CST5 
gene is downregulated during colon tumorigenesis associated with tumor dedifferentiation. 
Previously, cystatin D expression had only been detected in saliva and tears 83. The loss of 
cystatin D expression during colon tumorigenesis associated to dedifferentiation supports a 
role for this protein in the control of cell phenotype in vivo, and emphasizes its nature as a 
candidate tumor suppressor. Analogously, cystatin E/M has recently been shown to be 
downregulated in glioma, breast, prostate and cervical cancers 150,250,251,265,310. Likewise, 
cystatin C is downregulated in approximately 50% of human malignancies, particularly in 
cancers of the stomach, uterus, colon, and kidney (276 and references therein). Moreover, 
cystatin A is lost along the transformation of myoepithelial cells during tumorigenesis in most 
breast and prostate cancer, as well as in head and neck squamous cell carcinomas 
(HNSCC) and in brain tumors 66,162,165,174,272,283,284. Furthermore, high level of cystatin B 
correlates with increased probability of survival in patients with non-small cell lung cancer 
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and is downregulated in many breast cancers 165,166,173,316. It is known that cystatins are 
epigenetically silenced through DNA methylation-dependent mechanisms in several forms of 
cancer, including breast, pancreatic, brain, and lung (reviewed in 259). For this reason we 
studied whether the same mechanism occurred in case of cystatin D. We used Methyl Primer 
Express v1.0 software (Applied Biosystems) to identify CpG islands in an interval of 2.0 kb 
upstream and 1.5 kb downstream from the first ATG codon. The search was negative. 
Therefore, CST5 gene most probably lacks CpG islands in the vicinity of its promoter and 
thus the silencing mechanism based on CpG islands hypermethylation is not responsible for 
cystatin D repression. 
We also found a correlation between cystatin D expression and VDR protein levels in 
colon biopsies supporting a role of 1α,25(OH)2D3 in the regulation of cystatin D in the 
organism. Remarkably, VDR expression is associated with cell differentiation, absence of 
node involvement and favourable prognosis in colorectal cancer 52,71,236,309, which is in line 
with the loss of cystatin D in poorly differentiated tumors. Also the direct correlation between 
the expression of cystatin D and E-cadherin, which is a marker and crucial regulator of the 
epithelial phenotype and invasion, further supports the relation of cystatin D with tumor 
differentiation. 
Together, our findings reveal an unpredicted activity of cystatin D as tumor suppressor. 
According to the results with tumor biopsies, cystatin D also plays putative protective effects 
in humans. Furthermore, our results illustrate a novel mechanism of the anticancer action of 
the most active vitamin D metabolite and rationalize its preventive and therapeutic use 
against colon cancer. 
 
 
4. Gene expression profile induced by cystatin D 
 
Our observations that cystatin D is able to reduce cell proliferation and migration, as well as 
to increase cell adhesion suggest that it might behave like an autocrine factor regulating 
cellular properties. Some of these effects of cystatin D are independent on the inhibition of 
cathepsins activity. To explore this hypothesis, we have used DNA microarray analysis to 
define the gene expression profile induced by cystatin D. The categories of cell adhesion, 
transcription, and signal transduction were the most represented among genes whose RNA 
levels change by exogenous cystatin D expression: 35 out of 69 regulated genes were 
related with these processes.  
To our knowledge, this is the second study showing that a cystatin has the capacity to 
modify gene expression. Only one previous study had shown that cystatin E/M alters the 
gene expression profile of the MDA-MB-435S cancer cell line 278. The comparison with this 
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work reveals some similarities between the two cystatins. Thus, both regulate a similar 
number of genes (61 in case of cystatin E/M), with more genes downregulated than 
upregulated (41 versus 20 for cystatin E/M and 46 versus 23 for cystatin D). Moreover, in 
both cases a great number of target genes are related with signal transduction and/or 
transcription 278. Although these studies are performed in different systems (breast and colon 
cancer) and imply different molecules, the cellular functions regulated by both inhibitors are 
similar. Hence, it is possible that cystatins may be implicated in the control of overlapping 
processes. 
Of note, cystatin D expression exerts no compensatory effects on the expression of 
lysosomal cysteine proteases or another members of the cystatin superfamily. 
Among the genes regulated by cystatin D there are several transcription factors. Two 
members of the Runt-related transcription factors (RUNXs) are regulated in an opposite 
fashion. Thus, RUNX2 is upregulated by cystatin D whereas RUNX1 is downregulated. 
RUNX2 is known for its role in the differentiation of osteoblasts and chondrocytes from 
mesenchymal precursors 67,156,223,326. Osteocalcin (OCN) is the most established target gene 
for RUNX2 13,224. It is also known the key role that RUNX2 plays in the 1α,25(OH)2D3-
mediated upregulation of OCN in osteoblasts, by stabilizing through direct protein-protein 
interaction the binding of VDR to the VDREs present in the OCN promoter 231,232. Recently, 
RUNX2 has been proposed as a tumor suppressor 29,328 and some of the target genes that 
mediate its putative tumor suppressor activity are the cyclin-dependent kinase inhibitor 
p21WAF1/CIP1 or the pro-apoptotic protein BAX, both known 1α,25(OH)2D3 targets 65,328. 
RUNX1 is essential for the generation of hematopoietic stem cells and is involved in human 
leukemia 37,54. It is also known that RUNX1 induces transformation of 3T3 fibroblasts and 
stimulation of cell cycle progression 26,40,163,181,285, and recently, it has been related with 
lymphoma development (30 and references therein). These two genes, RUNX1 and RUNX2, 
have been validated by quantitative RT-PCR as cystatin D targets and further studies are 
necessary to elucidate the role that play in cystatin D actions.  
Cystatin D also regulates several genes related with cell adhesion such as CDH1, CLDN7 
(upregulated), VCAN or VIM (downregulated). CDH1 has been already validated along this 
Thesis as cystatin D target by quantitative RT-PCR and western blot, and the probable role 
of E-cadherin in cystatin D actions has been already discussed. CLDN7/claudin-7 encodes a 
member of the tight junctions that has an important role in the maintenance of the epithelial 
differentiated phenotype 157. It has been showed that ductal breast carcinoma and HNSCC 
have reduced expression of CLDN7 4,155. Moreover, reduced expression of CLDN7 is 
correlated with invasion and metastasis of squamous cell carcinoma of the esophagus 302. 
Likewise, CLDN7 expression diminishes during colon cancer progression and is correlated 
with liver metastasis 201,222. VCAN/versican, encodes a chondroitin sulfate proteoglycan that 
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is one of the main components of the extracellular matrix. Recent data suggest that VCAN 
modulates cell adhesion, proliferation, and migration. Hence, it plays a central role in tissue 
development and maintenance as well as in a number of pathologic processes (reviewed in 
257). Thus, increased expression of VCAN is strongly associated with poor outcome in many 
types of cancer 257. VIM/vimentin encodes an intermediate filament protein, well-known 
marker for EMT that is expressed in mesenchymal cells 88.  Several studies have 
demonstrated a functional contribution of vimentin to epithelial cell invasion and migration in 
numerous cell types 60,61,87,115,336. Moreover, a correlation has been suggested between 
vimentin expression and the perturbation of E-cadherin-mediated cell adhesion during cell 
migration. For instance, several studies comparing highly invasive breast or lung cell lines 
revealed that the loss of E-cadherin is associated with vimentin expression 243,277. Due to 
these data the three genes CLDN7, VCAN, and VIM are attractive targets of cystatin D. 
VCAN has been already validated by quantitative RT-PCR while future validation is needed 
for CLDN7 and VIM.  
Among the genes regulated by cystatin D that are related with signal transduction it is 
worth mentioning NAV3. This gene is strongly downregulated, as validated by quantitative 
RT-PCR. Little is known about NAV3, a member of the neuron navigator family of 
homologues of unc-53, a gene involved in axon guidance in Caenorhabditis elegans 182. 
However, it was recently included by Vogelstein’s group in the genomic landscape of human 
breast and colorectal cancers 318. In these studies, the authors propose that the genomic 
landscape of these two neoplasias are composed of a handful of commonly mutated gene 
“mountains” and a much larger number of gene “hills” that are mutated at low frequency. 
NAV3 is proposed as one of the “hill” genes implied in colorectal cancer 318, but no functional 
studies have showed relation of NAV3 with colon cancer yet. However, the strong regulation 
that cystatin D seems to exert over this gene together with its plausible role in colon 
neoplasia makes the study highly attractive. 
Notably, all the candidate cystatin D target genes related with metabolism are 
downregulated. NT5E and TXN are two of these genes and both are overexpressed in a 
variety of tumors. NT5E/CD73 encodes an enzyme that catalyzes the dephosphorylation of 
ribo- and deoxyribo-nucleotide 5’-monophosphates to their corresponding nucleosides, and 
is highly expressed in carcinomas of colon, lung, pancreas and ovary. Moreover, its 
expression level has been associated with tumor neovascularization, invasiveness, and 
metastasis, and with shorter patient survival 23,313. TXN/thioredoxin encodes a protein related 
with the regulation of cellular redox homeostasis. TXN contributes to many of the hallmarks 
of cancer including increased proliferation, resistance to cell death and increased 
angiogenesis, and is overexpressed in lung, breast, pancreatic, cervical, gastric and colon 
carcinomas 248,249.  
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Remarkably, a 4% of genes regulated by cystatin D are involved in RNA splicing. RBM35A 
is one of these genes, and a recently published study proposes it as a novel tumor 
suppressor for colorectal cancer 171. The authors propose that RBM35A suppresses the 
malignant potential on LS180 colon cancer cells through a mechanism of translational 
regulation of gene expression. The finding that cystatin D induces its expression on colon 
cancer cells suggests a possible role of this gene in the antitumor activity of cystatin D. 
Further studies are required to corroborate if these candidate target genes play a role in 
cystatin D actions and, if so, to elucidate their mechanism and importance. 
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1. 1α,25(OH)2D3 induces the expression of CST5 gene by direct activation of its 
promoter causing an increase in cystatin D RNA and protein levels in human colon 
cancer cells. 
 
2. Ectopic cystatin D expression mimics partially the effects of 1α,25(OH)2D3 in SW480-
ADH cells. CST5 knock-down by stable shRNA expression attenuates these effects. 
 
3. Exogenous cystatin D inhibits several transformation processes as proliferation, 
migration, and anchorage-independent growth of cultured colon cancer cells and their 
tumorigenesis in immunodeficient mice. 
 
4. Ectopic cystatin D expression represses c-MYC oncogene and inhibits Wnt/β-catenin 
signaling, which play a central role during CRC progression. 
 
5. Exogenous cystatin D induces an adhesive phenotype by increasing E-cadherin and 
other intercellular adhesion proteins expression and inhibits several inducers of 
epithelial-mesenchymal transition such as SNAI1, SNAI2, ZEB1 and ZEB2. 
 
6. Mutant cystatin D proteins with reduced antiproteolytic activity maintain the 
antiproliferative but not the migration-inhibitory activity. 
 
7. Cystatin D expression decreases during human colorectal tumorigenesis associated 
with tumor dedifferentiation and correlates with VDR and E-cadherin loss.  
 
8. Exogenous cystatin D distinctly alters the expression of a number of genes encoding 
proteins with different cellular functions.  
 
 
 
In summary, cystatin D is a novel 1α,25(OH)2D3 target in human colon cancer cells that 
behaves as a candidate tumor suppressor contributing to its protective effects against this 
neoplasia by antiproteolytic-dependent and -independent mechanisms. 
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1. La 1α,25(OH)2D3 induce, en células humanas de cáncer de colon, la expresión del 
gen CST5 mediante la activación directa de su promotor, aumentando sus niveles de 
RNA y proteína. 
 
2. La expresión ectópica de cistatina D mimetiza parcialmente los efectos de la 
1α,25(OH)2D3 en las células SW480-ADH, mientras que el silenciamiento del gen 
CST5 mediante la expresión estable de shRNA atenúa estos efectos. 
 
3. La cistatina D exógena inhibe diversos procesos de transformación tumoral como 
proliferación, migración y crecimiento independiente de anclaje a sustrato de células 
de cáncer colon, así como su capacidad tumorogénica en ratones inmunosuprimidos. 
 
4. La expresión ectópica de cistatina D reprime al oncogén c-MYC e inhibe la ruta de 
señalización Wnt/β-catenina, los cuales juegan un papel crucial durante la progresión 
del CRC. 
 
5. La cistatina D exógena induce un fenotipo adhesivo aumentando la expresión de E-
cadherina y otras proteínas de adhesión intercelular e inhibe la expresión de varios 
genes inductores de transición epitelio-mesénquima como SNAI1, SNAI2, ZEB1 y 
ZEB2. 
 
6. Mutantes de cistatina D con reducida actividad antiproteolítica mantienen la actividad 
antiproliferativa pero no la inhibición de la migración celular. 
 
7. La expresión de cistatina D disminuye durante la tumorogénesis colorrectal humana 
asociada con la desdiferenciación tumoral y se correlaciona con la pérdida de 
expresión de VDR y E-cadherina. 
 
8. La cistatina D exógena altera la expresión de un cierto número de genes que 
codifican proteínas implicadas en diferentes funciones celulares. 
 
 
En resumen, la cistatina D es una nueva diana de la 1α,25(OH)2D3 en células humanas 
de cáncer de colon, que se comporta como un posible supresor tumoral contribuyendo a 
los efectos de la 1α,25(OH)2D3 frente a esta neoplasia mediante mecanismos 
dependientes e independientes de su actividad antiproteolítica. 
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